azathioprine has been researched along with Proteinuria in 202 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of tacrolimus (TAC) and mycophenolate mofetil (MMF) for the initial therapy of lupus nephritis (LN)." | 9.22 | Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. ( Mok, CC; Ng, WL; Siu, YP; To, CH; Tong, KH; Yim, CW; Ying, KY, 2016) |
| "To report the 10-year follow-up of the MAINTAIN Nephritis Trial comparing azathioprine (AZA) and mycophenolate mofetil (MMF) as maintenance therapy of proliferative lupus nephritis, and to test different definitions of early response as predictors of long-term renal outcome." | 9.22 | Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. ( Ayala Guttierez, Mdel M; Blockmans, D; Cervera, R; D'Cruz, D; Depresseux, G; Fiehn, C; Gilboe, IM; Guillevin, L; Houssiau, FA; le Guern, V; Ravelingien, I; Remy, P; Sangle, S; Tamirou, F; Tektonidou, M; Vasconcelos, C, 2016) |
| "The objectives of this study are to analyse the long-term follow-up of a randomised controlled trial of induction treatment with azathioprine/methylprednisolone (AZA/MP) versus high-dose intravenous cyclophosphamide (ivCY) in patients with proliferative lupus nephritis (LN) and to evaluate the predictive value of clinical, laboratory and renal biopsy parameters regarding renal outcome." | 9.16 | Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. ( Arends, S; Berden, JH; Berger, SP; Bijl, M; de Sévaux, RG; Derksen, RH; Grootscholten, C; Voskuyl, AE, 2012) |
| " Nevertheless, increasing data have demonstrated that sirolimus (SRL), the first mTOR introduced in the treatment of solid organ transplant recipients, induces proteinuria, an adverse event that could produce deterioration of long-term renal function." | 9.12 | Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. ( Benavente, D; Buckel, E; Contreras, L; Ferrario, M; Fierro, A; Herzog, C; Morales, J; Zehnder, C, 2007) |
| "Recent studies have reported a significant increase of proteinuria in kidney transplant recipients who were switched from a calcineurin inhibitor (CI) to sirolimus." | 9.12 | Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. ( Hoitsma, AJ; van den Akker, JM; Wetzels, JF, 2006) |
| " The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment." | 9.10 | Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2003) |
| "Thirty-eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low-dose corticosteroid treatment and have been followed for a mean of 21/3 years thereafter." | 9.04 | Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. ( Decker, JL; Klippel, JH; Plotz, PH; Steinberg, AD, 1975) |
| "In a controlled trial, symptomatic treatment alone, or 12 weeks of cyclophosphamide or azathioprine were compared in Nigerian children with nephrotic syndrome (mainly quartan malarial nephropathy) and poorly selective proteinuria." | 9.04 | A controlled trial of cyclophosphamide and azathioprine in Nigerian children with the nephrotic syndrome and poorly selective proteinuria. ( Adeniyi, A; Hendrickse, RG; Soothill, JF, 1979) |
| "In a controlled double-blind trial five patients with the nephrotic syndrome due to idiopathic membranous glomerulonephritis received azathioprine, 2." | 9.04 | Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. ( , 1976) |
| "A controlled trial in 20 adult patients with the nephrotic syndrome due to proliferative glomerulonephritis compared the effects of consecutive eight-week courses of treatment with prednisolone in conventional dosage and a low-dose azathioprine-prednisolone combination." | 9.03 | Nephrotic syndrome due to primary renal disease in adults: II. A controlled trial of prednisolone and azathioprine. ( Cameron, JS; Ogg, CS; Sharpstone, P, 1969) |
| "Azathioprine may be beneficial in the treatment of IgA vasculitis with renal involvement." | 7.91 | The profile and clinical outcomes of patients with renal involvement due to IgA vasculitis: is azathioprine a good option for treatment? ( Andrade, MC; Clemente, G; Fernandez, JD; Fraga, MM; Len, CA; Schinzel, V; Terreri, MT, 2019) |
| "A retrospective single-center cohort study was conducted on 35 patients with diffuse proliferative (WHO type IV) and/or membranous (type V) lupus nephritis (22 with type IV, 6 with type V, and 7 with type IV plus V) who had been treated with a sequential regimen comprising prednisolone and cyclophosphamide during active disease, followed by low-dose prednisolone and azathioprine maintenance." | 7.69 | Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. ( Chan, KW; Chan, TM; Cheng, IK; Li, FK; Wong, KL; Wong, RW, 1995) |
| "The possibility that hyperlipidemia and an increase of mononuclear cells in the glomeruli could participate in the pathogenesis of minimal change glomerulopathy was evaluated in puromycin aminonucleoside (PAN) nephrosis in rats." | 7.69 | The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats. ( Hattori, T; Ito, M; Nagamatsu, T; Suzuki, Y, 1996) |
| " It was evaluated, in comparison with azathioprine (AZA) and methylprednisolone acetate (MPA), for its therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against the rat glomerular basement membrane." | 7.68 | Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Inoue, T; Ogawa, T, 1991) |
| "Thirteen adult patients with nephrotic syndrome resistant to corticosteroid administration were treated with azathioprine daily for four years." | 7.67 | Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. ( Cade, R; Campbell, K; Croker, B; Mars, D; Peterson, J; Privette, M; Thompson, R, 1986) |
| "In this paper, the effect of the administration of prednisone and azathioprine on an experimental immune complex glomerulonephritis is studied." | 7.65 | Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. II. Influence of medication with prednisone and azathioprine: a histologic and immunohistologic study at the light microscopic and the ultrastructural leve ( Arends, A; Feenstra, K; Greben, HA; Hoedemaeker, PJ; van den Lee, R, 1975) |
| "For patients with diffuse proliferative lupus nephritis, azathioprine or cyclosporine combined with corticosteroids demonstrated equal efficacy in the prevention of flares." | 6.72 | A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. ( Alberighi, OD; Altieri, P; Doria, A; Ferraccioli, G; Ferrara, R; Greco, S; Manno, C; Moroni, G; Mosca, M; Ponticelli, C; Todesco, S, 2006) |
| " The risk of major adverse events is low in patients with normal renal function but increases in those with impaired renal function and with the addition of azathioprine." | 6.53 | Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. ( Alberghini, E; Baragetti, I; Buzzi, L; De Silvestri, A; Del Vecchio, L; Ferrario, F; Pani, A; Pozzi, C; Sarcina, C; Scaini, P; Tinelli, C, 2016) |
| "The treatment of membranous lupus nephritis (MLN) is still controversial in the literature." | 5.37 | Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis. ( Alves de Brito, G; Bitencourt Dias, C; Dos Santos Silva, V; Gera Abrão, J; Malafronte, P; Pinheiro, CC; Titan, S; Toledo Barros, R; Woronik, V, 2011) |
| "To report the 10-year follow-up of the MAINTAIN Nephritis Trial comparing azathioprine (AZA) and mycophenolate mofetil (MMF) as maintenance therapy of proliferative lupus nephritis, and to test different definitions of early response as predictors of long-term renal outcome." | 5.22 | Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. ( Ayala Guttierez, Mdel M; Blockmans, D; Cervera, R; D'Cruz, D; Depresseux, G; Fiehn, C; Gilboe, IM; Guillevin, L; Houssiau, FA; le Guern, V; Ravelingien, I; Remy, P; Sangle, S; Tamirou, F; Tektonidou, M; Vasconcelos, C, 2016) |
| "To compare the efficacy of tacrolimus (TAC) and mycophenolate mofetil (MMF) for the initial therapy of lupus nephritis (LN)." | 5.22 | Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. ( Mok, CC; Ng, WL; Siu, YP; To, CH; Tong, KH; Yim, CW; Ying, KY, 2016) |
| "The objectives of this study are to analyse the long-term follow-up of a randomised controlled trial of induction treatment with azathioprine/methylprednisolone (AZA/MP) versus high-dose intravenous cyclophosphamide (ivCY) in patients with proliferative lupus nephritis (LN) and to evaluate the predictive value of clinical, laboratory and renal biopsy parameters regarding renal outcome." | 5.16 | Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. ( Arends, S; Berden, JH; Berger, SP; Bijl, M; de Sévaux, RG; Derksen, RH; Grootscholten, C; Voskuyl, AE, 2012) |
| "To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis." | 5.14 | The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. ( Abramovicz, D; Blockmans, D; Cattaneo, R; Cauli, A; Cervera, R; Cosyns, JP; D'Cruz, D; Danieli, MG; de Ramon Garrido, E; Depresseux, G; Direskeneli, H; Font, J; Galeazzi, M; Gül, A; Houssiau, FA; Levy, Y; Petera, P; Petrovic, R; Popovic, R; Sebastiani, GD; Sinico, RA; Vasconcelos, C, 2010) |
| "Recent studies have reported a significant increase of proteinuria in kidney transplant recipients who were switched from a calcineurin inhibitor (CI) to sirolimus." | 5.12 | Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. ( Hoitsma, AJ; van den Akker, JM; Wetzels, JF, 2006) |
| " Nevertheless, increasing data have demonstrated that sirolimus (SRL), the first mTOR introduced in the treatment of solid organ transplant recipients, induces proteinuria, an adverse event that could produce deterioration of long-term renal function." | 5.12 | Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria. ( Benavente, D; Buckel, E; Contreras, L; Ferrario, M; Fierro, A; Herzog, C; Morales, J; Zehnder, C, 2007) |
| "In the Euro-Lupus Nephritis Trial (ELNT), 90 patients with lupus nephritis were randomly assigned to a high-dose intravenous cyclophosphamide (IV CYC) regimen (6 monthly pulses and 2 quarterly pulses with escalating doses) or a low-dose IV CYC regimen (6 pulses of 500 mg given at intervals of 2 weeks), each of which was followed by azathioprine (AZA)." | 5.11 | Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. ( Abramovicz, D; Blockmans, D; Cattaneo, R; Cervera, R; Cosyns, JP; D'Cruz, D; Danieli, MG; de Ramon Garrido, E; Depresseux, G; Direskeneli, H; Font, J; Galeazzi, M; Gül, A; Houssiau, FA; Levy, Y; Mathieu, A; Petera, P; Petrovic, R; Popovic, R; Sebastiani, GD; Sinico, RA; Vasconcelos, C, 2004) |
| " The aim of this study was to evaluate the effects of losartan on proteinuria and renal function in patients with FSGS refractory to immunosuppressive treatment." | 5.10 | Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. ( Dilek, K; Ersoy, A; Güllülü, M; Ozdemir, B; Usta, M; Yavuz, M; Yurtkuran, M, 2003) |
| "In a controlled double-blind trial five patients with the nephrotic syndrome due to idiopathic membranous glomerulonephritis received azathioprine, 2." | 5.04 | Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. ( , 1976) |
| "Thirty-eight patients with diffuse glomerulonephritis of systemic lupus erythematosus were randomly assigned to add cyclophosphamide, azathioprine, or nothing to low-dose corticosteroid treatment and have been followed for a mean of 21/3 years thereafter." | 5.04 | Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months. ( Decker, JL; Klippel, JH; Plotz, PH; Steinberg, AD, 1975) |
| "Patients with various forms of glomerulonephritis, but excluding those with minimal glomerular changes, were admitted to a controlled trial of a regimen which combined azathioprine in a dosage of 2." | 5.03 | Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party. ( , 1971) |
| "A controlled trial in 20 adult patients with the nephrotic syndrome due to proliferative glomerulonephritis compared the effects of consecutive eight-week courses of treatment with prednisolone in conventional dosage and a low-dose azathioprine-prednisolone combination." | 5.03 | Nephrotic syndrome due to primary renal disease in adults: II. A controlled trial of prednisolone and azathioprine. ( Cameron, JS; Ogg, CS; Sharpstone, P, 1969) |
| " The factors associated with a lower probability of recovery included a previous history of LN flares, worse eGFR and higher proteinuria at presentation, immunosuppression with azathioprine, and hospitalizations within 6 months of therapy initiation." | 4.31 | Predictors of treatment outcomes in lupus nephritis with severe acute kidney injury and requirement of dialytic support. ( Juárez-Cuevas, B; Márquez-Macedo, SE; Mejía-Vilet, JM; Morales-Buenrostro, LE; Navarro-Gerrard, MA; Pena-Vizcarra, ÓR; Perez-Arias, AA; Zavala-Miranda, MF, 2023) |
| "Azathioprine may be beneficial in the treatment of IgA vasculitis with renal involvement." | 3.91 | The profile and clinical outcomes of patients with renal involvement due to IgA vasculitis: is azathioprine a good option for treatment? ( Andrade, MC; Clemente, G; Fernandez, JD; Fraga, MM; Len, CA; Schinzel, V; Terreri, MT, 2019) |
| "Children with IgA nephropathy showing diffuse (>80%) mesangial proliferation are at high risk for end-stage renal failure (ESRF)." | 3.85 | Long-term results of a randomized controlled trial in childhood IgA nephropathy. ( Hataya, H; Honda, M; Iijima, K; Ishikura, K; Ito, S; Kamei, K; Nakanishi, K; Saito, M; Sako, M; Yoshikawa, N, 2011) |
| " The aim of this study was to evaluate the outcome of a conversion from CNI-based immunosuppressive protocol to sirolimus (SRL) in recipients with graft in chronic kidney disease (CKD) grade III and proteinuria below 500 mg/day." | 3.79 | Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011. ( Aleksić, P; Drasković-Pavlović, B; Dujić, A; Hrvacević, R; Ignjatović, L; Jovanović, D; Karan, Z; Kovacević, Z; Maksić, D; Rabrenović, V; Tomić, A; Vavić, N, 2013) |
| "9 g 24-h proteinuria while still in remission of the protein-losing enteropathy, receiving 5 mg prednisone and 100 mg azathioprine daily." | 3.78 | Protein-losing enteropathy as initial manifestation of systemic lupus erythematosus. ( Braga, LL; Brandão, LA; Carneiro, FO; Rocha, FA; Sampaio, LR, 2012) |
| " In addition, we suppressed the immune system with either azathioprine (Aza) or mycophenolate mofetil (MMF) during the second half of pregnancy to determine whether the these symptoms could be ameliorated." | 3.75 | Immunosuppression improves blood pressure and endothelial function in a rat model of pregnancy-induced hypertension. ( Chiasson, VL; Mahajan, A; Mitchell, BM; South, S; Tinsley, JH, 2009) |
| "Treatment with prednisolone and azathioprine is beneficial in ameliorating the clinical course of a subset of IgAN patients with heavy proteinuria or impaired renal function." | 3.72 | Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study. ( Ahuja, M; Brown, CB; Davlouros, P; El Nahas, AM; Goumenos, DS; Shortland, JR; Vlachojannis, JG, 2003) |
| " cadaveric donor), colchicine dose, presence of proteinuria, and immunosuppression protocol (CsA-based triple drug therapy vs." | 3.71 | Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers. ( Ayalon, A; Ben-Haim, M; Kuriansky, J; Lustig, S; Malinger-Saavedra, P; Rosin, D; Shabtai, EL; Shabtai, M; Shapira, Z; Zemer, D, 2002) |
| " The effect of treatment with prednisolone and azathioprine in patients with nephrotic-range proteinuria and biopsy-proven IMN from a single center (Sheffield Kidney Institute, Sheffield, UK) is described." | 3.70 | Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? ( Ahuja, M; Brown, CB; Gerakis, A; Goumenos, D; Shortland, JR, 1999) |
| "A retrospective single-center cohort study was conducted on 35 patients with diffuse proliferative (WHO type IV) and/or membranous (type V) lupus nephritis (22 with type IV, 6 with type V, and 7 with type IV plus V) who had been treated with a sequential regimen comprising prednisolone and cyclophosphamide during active disease, followed by low-dose prednisolone and azathioprine maintenance." | 3.69 | Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. ( Chan, KW; Chan, TM; Cheng, IK; Li, FK; Wong, KL; Wong, RW, 1995) |
| "The possibility that hyperlipidemia and an increase of mononuclear cells in the glomeruli could participate in the pathogenesis of minimal change glomerulopathy was evaluated in puromycin aminonucleoside (PAN) nephrosis in rats." | 3.69 | The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats. ( Hattori, T; Ito, M; Nagamatsu, T; Suzuki, Y, 1996) |
| " It was evaluated, in comparison with azathioprine (AZA) and methylprednisolone acetate (MPA), for its therapeutic effects on the glomerulonephritis induced in rats by rabbit antiserum against the rat glomerular basement membrane." | 3.68 | Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats. ( Gotoh, K; Hayashi, S; Inazu, M; Inoue, T; Ogawa, T, 1991) |
| "Thirteen adult patients with nephrotic syndrome resistant to corticosteroid administration were treated with azathioprine daily for four years." | 3.67 | Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. ( Cade, R; Campbell, K; Croker, B; Mars, D; Peterson, J; Privette, M; Thompson, R, 1986) |
| " Amelioration of proteinuria and the plasma coagulation defect followed therapy with corticosteroids and azathioprine." | 3.65 | Factor IX deficiency in the nephrotic syndrome: studies with prothrombin complex concentrate. ( Natelson, EA; Rahman, F; Zanger, B, 1975) |
| "In this paper, the effect of the administration of prednisone and azathioprine on an experimental immune complex glomerulonephritis is studied." | 3.65 | Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. II. Influence of medication with prednisone and azathioprine: a histologic and immunohistologic study at the light microscopic and the ultrastructural leve ( Arends, A; Feenstra, K; Greben, HA; Hoedemaeker, PJ; van den Lee, R, 1975) |
| " The rapid progression of both diseases forced us to start an immunosuppressive drug therapy using azathioprine and steroids, 18 months after the beginning of the treatment the patient is well, has only slight proteinuria, normal levels of complement and no joint pain." | 3.65 | [Mesangiocapillary glomerulonephritis and rheumatoid arthritis. A case with diagnostic and therapeutic questions (author's transl)]. ( Bürkle, PA; Federlin, K; Franz, HE; Tönnesmann, E, 1976) |
| "The clinical course of IgA nephropathy (IgAN) and its outcome are extremely variable." | 2.82 | Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy. ( Corghi, E; De Silvestri, A; De Simone, I; Del Vecchio, L; Ferrario, F; Furiani, S; Pani, A; Pozzi, C; Santagostino, G; Sarcina, C; Terraneo, V; Tinelli, C; Visciano, B, 2016) |
| "A fall in proteinuria was recorded in both groups during treatment, but it rose significantly in Aza group (1." | 2.76 | Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study. ( Basta-Jovanovic, G; Jovanovic, D; Marinkovic, J; Naumovic, R; Pavlovic, S; Stosovic, M, 2011) |
| "The optimal treatment for IgA nephropathy (IgAN) remains unknown." | 2.75 | Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. ( Allegri, L; Andrulli, S; Cirami, L; De Cristofaro, V; Del Vecchio, L; Fogazzi, G; Locatelli, F; Pani, A; Pozzi, C; Procaccini, AD; Scaini, P; Vogt, B, 2010) |
| "For patients with diffuse proliferative lupus nephritis, azathioprine or cyclosporine combined with corticosteroids demonstrated equal efficacy in the prevention of flares." | 2.72 | A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. ( Alberighi, OD; Altieri, P; Doria, A; Ferraccioli, G; Ferrara, R; Greco, S; Manno, C; Moroni, G; Mosca, M; Ponticelli, C; Todesco, S, 2006) |
| "Proteinuria has significantly reduced in 10 patients, and only four patients still have nephrotic-range proteinuria." | 2.69 | Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. ( Brown, JH; Doherty, CC; Douglas, AF; Hill, CM; McNamee, PT; Murphy, BG; Nelson, WE, 1998) |
| "Treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole early in the course of disease may prevent immunologic renal injury in children with severe IgA nephropathy." | 2.69 | A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. ( Awazu, M; Hattori, S; Honda, M; Iitaka, K; Ito, H; Ito, K; Koitabashi, Y; Matsuyama, S; Nakagawa, K; Nakamura, H; Ninomiya, M; Sakai, T; Seino, Y; Takeda, N; Takekoshi, Y; Yamaoka, K; Yoshikawa, N, 1999) |
| " Prednisolone dosage was gradually tapered to 10 mg/d at 6 months, when cyclophosphamide was replaced by azathioprine (2 mg/kg/d p." | 2.69 | Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. ( Chan, KW; Chan, TM; Hao, WK; Lai, KN; Li, FK; Lui, SL; Tang, S, 1999) |
| " The risk of major adverse events is low in patients with normal renal function but increases in those with impaired renal function and with the addition of azathioprine." | 2.53 | Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. ( Alberghini, E; Baragetti, I; Buzzi, L; De Silvestri, A; Del Vecchio, L; Ferrario, F; Pani, A; Pozzi, C; Sarcina, C; Scaini, P; Tinelli, C, 2016) |
| "Children with systemic lupus erythematosus and nephritis may benefit from the addition of cytotoxic agents to their corticosteroid regime, although the indications for this are not clear, and controlled evidence is lacking." | 2.36 | Immunosuppressive agents in the treatment of the nephrotic syndrome and glomerulonephritis in children. ( Cameron, JS, 1979) |
| "Azathioprine was switched to mycophenolate mofetil, and the patient showed significant improvement in proteinuria." | 1.91 | Fibrillar glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis. ( Patrick, J; Thirunavukkarasu, S; Whelband, MC; Willingham, T, 2023) |
| "Nephritis occurs frequently in systemic lupus erythematosus (SLE) and may worsen disease morbidity and mortality." | 1.56 | Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center. ( Delfino, J; Dos Santos, TAFG; Skare, TL, 2020) |
| "Suggestion for the management of idiopathic membranous nephropathy (IMN) includes 6 months of observation, followed with steroid plus alkylating agent." | 1.46 | Early initiation of immunosuppressive treatment in membranous nephropathy patients. ( Chan, CK; Chen, PM; Chen, YM; Chiang, WC; Chiu, YL; Chou, YH; Chu, TS; Lai, TS; Wu, CF; Wu, KD, 2017) |
| "The evolution toward chronic renal failure was observed in three patients." | 1.46 | [Idiopathic nephrotic syndrome (INS) in children in Dakar: about 40 cases]. ( Dial, CM; Diouf, B; Ka, EHF; Keita, Y; Lemrabott, AT; Moreira, C; Ndiaye, O; Ndongo, AA; Niang, A; Niang, B; Sall, MG; Sow, A; Sylla, A, 2017) |
| "Fabry's disease is a rare X-linked, hereditary lysosomal storage disease caused by a deficiency of the enzyme α-galactosidase A." | 1.40 | A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link. ( Hanaoka, H; Hashiguchi, A; Ishii, T; Konishi, K; Kuwana, M, 2014) |
| "The treatment of membranous lupus nephritis (MLN) is still controversial in the literature." | 1.37 | Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis. ( Alves de Brito, G; Bitencourt Dias, C; Dos Santos Silva, V; Gera Abrão, J; Malafronte, P; Pinheiro, CC; Titan, S; Toledo Barros, R; Woronik, V, 2011) |
| "The renal biopsy was performed and IgA nephropathy (type IV) was diagnosed." | 1.35 | [Crohn's disease in association with IgA nephropathy]. ( Choi, YJ; Chung, WC; Kim, HW; Lee, JM; Lee, JR; Lee, KM; Paik, CN; Yang, JM, 2008) |
| "Primary systemic sclerosis (PSS) is such a disease characterised by multi-organ fibrosis." | 1.35 | Graves' disease associated with primary systemic sclerosis. ( Wimmersberger, Y; Zuercher, D, 2009) |
| " POCY was given for 2 to 4 mo at a dosage of 1." | 1.35 | Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. ( Hackshaw, KV; Hebert, LA; McKinley, A; Nagaraja, S; Park, E; Rovin, BH; Spetie, D, 2009) |
| "Idiopathic membranous nephropathy (IMN) is the most common cause of nephrotic syndrome in adults." | 1.33 | Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. ( Ahuja, M; Brown, CB; Davlouros, P; El Nahas, AM; Goumenos, DS, 2006) |
| "Treatment with azathioprine and prednisone was associated with elevated serum levels of examined lipids." | 1.32 | Renal function and lipid metabolism in pregnant renal transplant recipients. ( Czajkowski, K; Grymowicz, M; Malinowska-Polubiec, A; Romejko, E; Sieńko, J; Smolarczyk, R; Wójcicka-Bentyn, J, 2004) |
| " The most significant factor responsible for these metabolic complications was the total dosage of prednisone and cyclosporine." | 1.29 | Metabolic problems in recipients of liver transplants. ( Filo, RS; Hughes, D; Jindal, RM; Leapman, SB; Lumeng, L; Milgrom, ML; Pescovitz, MD; Sidner, RA, 1996) |
| "These data suggest that long-term renal function in cyclosporine-treated kidney transplant patients is primarily influenced by the occurrence of early and late rejection episodes rather than by the dosage or duration of cyclosporine therapy." | 1.29 | Long-term renal function in cyclosporine-treated renal allograft recipients. ( Hodge, E; Novick, AC; Streem, S; Tanabe, K, 1995) |
| "Treatment with prednisolone or cytostatic drugs as single therapy for up to 6 months increased the risk of improvement of the disease, and had no significant effect on deterioration." | 1.28 | Prognosis in glomerulonephritis. III. A longitudinal analysis of changes in serum creatinine and proteinuria during the course of disease: effect of immunosuppressive treatment. Report from Copenhagen Study Group of Renal Diseases. ( Balsløv, JT; Brahm, M; Brammer, M; Brun, C; Gerstoft, J; Jørgensen, HE; Lorenzen, I; Thomsen, AC, 1992) |
| "To evaluate the rate of recurrence of focal segmental glomerulosclerosis (FSGS) in renal transplant patients treated with cyclosporine, we reviewed the outcome of 25 renal Tx performed in 24 patients who had FSGS as their original renal disease." | 1.28 | The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine. ( Banfi, G; Colturi, C; Montagnino, G; Ponticelli, C, 1990) |
| "End-stage renal disease (ESRD) was secondary to chronic glomerulonephritis (n = 9), diabetes mellitus (n = 6), polycystic kidney disease (n = 5), and miscellaneous causes (n = 11)." | 1.28 | The development of proteinuria and focal-segmental glomerulosclerosis in recipients of pediatric donor kidneys. ( Hayes, JM; Novick, AC; Steinmuller, DR; Streem, SB, 1991) |
| " Immunosuppression was generally reduced in the second trimester and was temporarily increased above the maintenance dosage after delivery." | 1.27 | [Pregnancy after kidney transplantation. Report of 6 successful cases with multiple risk factors]. ( Hengst, P; May, G; Mebel, M; Schilling, H; Schmitt, E; Scholz, D, 1983) |
| "The renal survival of 53 MPGN patients treated on a long-term basis by non-steroid anti-inflammatory drugs (NSAID) was compared to that of untreated MPGN patients previously reported in the literature." | 1.27 | Renal survival in membranoproliferative glomerulonephritis (MPGN): role of long-term treatment with non-steroid anti-inflammatory drugs (NSAID). ( Belghiti, D; Lagrue, G; Laurent, J, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 108 (53.47) | 18.7374 |
| 1990's | 28 (13.86) | 18.2507 |
| 2000's | 29 (14.36) | 29.6817 |
| 2010's | 33 (16.34) | 24.3611 |
| 2020's | 4 (1.98) | 2.80 |
| Authors | Studies |
|---|---|
| Whelband, MC | 1 |
| Willingham, T | 1 |
| Thirunavukkarasu, S | 1 |
| Patrick, J | 1 |
| Márquez-Macedo, SE | 1 |
| Perez-Arias, AA | 1 |
| Pena-Vizcarra, ÓR | 1 |
| Zavala-Miranda, MF | 1 |
| Juárez-Cuevas, B | 1 |
| Navarro-Gerrard, MA | 1 |
| Morales-Buenrostro, LE | 1 |
| Mejía-Vilet, JM | 1 |
| Delfino, J | 1 |
| Dos Santos, TAFG | 1 |
| Skare, TL | 1 |
| Fanouriakis, A | 1 |
| Kostopoulou, M | 1 |
| Cheema, K | 1 |
| Anders, HJ | 1 |
| Aringer, M | 1 |
| Bajema, I | 1 |
| Boletis, J | 1 |
| Frangou, E | 1 |
| Houssiau, FA | 4 |
| Hollis, J | 1 |
| Karras, A | 1 |
| Marchiori, F | 1 |
| Marks, SD | 1 |
| Moroni, G | 2 |
| Mosca, M | 2 |
| Parodis, I | 1 |
| Praga, M | 1 |
| Schneider, M | 1 |
| Smolen, JS | 1 |
| Tesar, V | 2 |
| Trachana, M | 1 |
| van Vollenhoven, RF | 1 |
| Voskuyl, AE | 2 |
| Teng, YKO | 1 |
| van Leew, B | 1 |
| Bertsias, G | 1 |
| Jayne, D | 1 |
| Boumpas, DT | 1 |
| Keita, Y | 1 |
| Lemrabott, AT | 1 |
| Sylla, A | 1 |
| Niang, B | 1 |
| Ka, EHF | 1 |
| Dial, CM | 1 |
| Ndongo, AA | 1 |
| Sow, A | 1 |
| Moreira, C | 1 |
| Niang, A | 1 |
| Ndiaye, O | 1 |
| Diouf, B | 1 |
| Sall, MG | 1 |
| Castro, M | 1 |
| Ugolini-Lopes, M | 1 |
| Borba, EF | 1 |
| Bonfá, E | 1 |
| Seguro, LPC | 1 |
| Schinzel, V | 1 |
| Fernandez, JD | 1 |
| Clemente, G | 1 |
| Fraga, MM | 1 |
| Andrade, MC | 1 |
| Len, CA | 1 |
| Terreri, MT | 1 |
| Matsuzaki, K | 1 |
| Suzuki, Y | 6 |
| Nakata, J | 1 |
| Sakamoto, N | 1 |
| Horikoshi, S | 1 |
| Kawamura, T | 1 |
| Matsuo, S | 1 |
| Tomino, Y | 1 |
| Stangou, M | 1 |
| Papagianni, A | 1 |
| Bantis, C | 1 |
| Moisiadis, D | 1 |
| Kasimatis, S | 1 |
| Spartalis, M | 1 |
| Pantzaki, A | 1 |
| Efstratiadis, G | 1 |
| Memmos, D | 1 |
| Bui, T | 1 |
| Chandrakasan, S | 1 |
| Poulik, J | 1 |
| Fathalla, BM | 1 |
| Hässig, A | 1 |
| Roos, M | 1 |
| Etter, A | 1 |
| Bossart, W | 1 |
| Müller, N | 1 |
| Schiesser, M | 1 |
| Wüthrich, RP | 1 |
| Fehr, T | 1 |
| Ignjatović, L | 1 |
| Hrvacević, R | 1 |
| Jovanović, D | 2 |
| Kovacević, Z | 1 |
| Vavić, N | 1 |
| Rabrenović, V | 1 |
| Tomić, A | 1 |
| Aleksić, P | 1 |
| Drasković-Pavlović, B | 1 |
| Dujić, A | 1 |
| Karan, Z | 1 |
| Maksić, D | 1 |
| Hanaoka, H | 1 |
| Hashiguchi, A | 1 |
| Konishi, K | 1 |
| Ishii, T | 1 |
| Kuwana, M | 1 |
| Mok, CC | 1 |
| Ying, KY | 1 |
| Yim, CW | 1 |
| Siu, YP | 1 |
| Tong, KH | 1 |
| To, CH | 1 |
| Ng, WL | 1 |
| Tamirou, F | 1 |
| D'Cruz, D | 3 |
| Sangle, S | 1 |
| Remy, P | 1 |
| Vasconcelos, C | 3 |
| Fiehn, C | 1 |
| Ayala Guttierez, Mdel M | 1 |
| Gilboe, IM | 1 |
| Tektonidou, M | 1 |
| Blockmans, D | 3 |
| Ravelingien, I | 1 |
| le Guern, V | 1 |
| Depresseux, G | 3 |
| Guillevin, L | 1 |
| Cervera, R | 3 |
| Hu, WX | 1 |
| Chen, YH | 1 |
| Bao, H | 1 |
| Liu, ZZ | 1 |
| Wang, SF | 1 |
| Zhang, HT | 1 |
| Liu, ZH | 1 |
| Maroz, N | 1 |
| Field, H | 1 |
| Fix, OK | 1 |
| Stock, PG | 1 |
| Lee, BK | 1 |
| Benson, MD | 1 |
| Sargin, G | 1 |
| Senturk, T | 1 |
| Cildag, S | 1 |
| Cabral, DA | 1 |
| Canter, DL | 1 |
| Muscal, E | 1 |
| Nanda, K | 1 |
| Wahezi, DM | 1 |
| Spalding, SJ | 1 |
| Twilt, M | 1 |
| Benseler, SM | 1 |
| Campillo, S | 1 |
| Charuvanij, S | 1 |
| Dancey, P | 1 |
| Eberhard, BA | 1 |
| Elder, ME | 1 |
| Hersh, A | 1 |
| Higgins, GC | 1 |
| Huber, AM | 1 |
| Khubchandani, R | 1 |
| Kim, S | 1 |
| Klein-Gitelman, M | 1 |
| Kostik, MM | 1 |
| Lawson, EF | 1 |
| Lee, T | 1 |
| Lubieniecka, JM | 1 |
| McCurdy, D | 1 |
| Moorthy, LN | 1 |
| Morishita, KA | 1 |
| Nielsen, SM | 1 |
| O'Neil, KM | 1 |
| Reiff, A | 1 |
| Ristic, G | 1 |
| Robinson, AB | 1 |
| Sarmiento, A | 1 |
| Shenoi, S | 1 |
| Toth, MB | 1 |
| Van Mater, HA | 1 |
| Wagner-Weiner, L | 1 |
| Weiss, JE | 1 |
| White, AJ | 1 |
| Yeung, RS | 1 |
| Sarcina, C | 2 |
| Tinelli, C | 2 |
| Ferrario, F | 2 |
| Pani, A | 3 |
| De Silvestri, A | 2 |
| Scaini, P | 2 |
| Del Vecchio, L | 3 |
| Alberghini, E | 1 |
| Buzzi, L | 1 |
| Baragetti, I | 1 |
| Pozzi, C | 3 |
| Visciano, B | 1 |
| De Simone, I | 1 |
| Terraneo, V | 1 |
| Furiani, S | 1 |
| Santagostino, G | 1 |
| Corghi, E | 1 |
| Chan, CK | 1 |
| Lai, TS | 1 |
| Chen, PM | 1 |
| Chou, YH | 1 |
| Wu, CF | 1 |
| Chiu, YL | 1 |
| Chiang, WC | 1 |
| Chen, YM | 1 |
| Chu, TS | 1 |
| Wu, KD | 1 |
| Lee, JM | 1 |
| Lee, KM | 1 |
| Kim, HW | 1 |
| Chung, WC | 1 |
| Paik, CN | 1 |
| Lee, JR | 1 |
| Choi, YJ | 1 |
| Yang, JM | 1 |
| Sebastiani, GD | 2 |
| de Ramon Garrido, E | 2 |
| Danieli, MG | 2 |
| Abramovicz, D | 2 |
| Cauli, A | 1 |
| Direskeneli, H | 2 |
| Galeazzi, M | 2 |
| Gül, A | 2 |
| Levy, Y | 2 |
| Petera, P | 2 |
| Popovic, R | 2 |
| Petrovic, R | 2 |
| Sinico, RA | 2 |
| Cattaneo, R | 2 |
| Font, J | 2 |
| Cosyns, JP | 2 |
| Tinsley, JH | 1 |
| Chiasson, VL | 1 |
| South, S | 1 |
| Mahajan, A | 1 |
| Mitchell, BM | 1 |
| McKinley, A | 1 |
| Park, E | 1 |
| Spetie, D | 1 |
| Hackshaw, KV | 1 |
| Nagaraja, S | 1 |
| Hebert, LA | 1 |
| Rovin, BH | 1 |
| Wimmersberger, Y | 1 |
| Zuercher, D | 1 |
| Andrulli, S | 1 |
| Fogazzi, G | 1 |
| Vogt, B | 1 |
| De Cristofaro, V | 1 |
| Allegri, L | 1 |
| Cirami, L | 1 |
| Procaccini, AD | 1 |
| Locatelli, F | 1 |
| Hiemstra, TF | 1 |
| Walsh, M | 1 |
| Mahr, A | 1 |
| Savage, CO | 1 |
| de Groot, K | 1 |
| Harper, L | 1 |
| Hauser, T | 1 |
| Neumann, I | 1 |
| Wissing, KM | 1 |
| Pagnoux, C | 1 |
| Schmitt, W | 1 |
| Jayne, DR | 1 |
| Hodson, EM | 1 |
| Willis, NS | 1 |
| Craig, JC | 1 |
| Naumovic, R | 1 |
| Pavlovic, S | 1 |
| Stosovic, M | 1 |
| Marinkovic, J | 1 |
| Basta-Jovanovic, G | 1 |
| Kamei, K | 1 |
| Nakanishi, K | 1 |
| Ito, S | 1 |
| Saito, M | 1 |
| Sako, M | 1 |
| Ishikura, K | 1 |
| Hataya, H | 1 |
| Honda, M | 2 |
| Iijima, K | 1 |
| Yoshikawa, N | 2 |
| Bitencourt Dias, C | 1 |
| Pinheiro, CC | 1 |
| Malafronte, P | 1 |
| Titan, S | 1 |
| Alves de Brito, G | 1 |
| Gera Abrão, J | 1 |
| Dos Santos Silva, V | 1 |
| Toledo Barros, R | 1 |
| Woronik, V | 1 |
| Carneiro, FO | 1 |
| Sampaio, LR | 1 |
| Brandão, LA | 1 |
| Braga, LL | 1 |
| Rocha, FA | 1 |
| Arends, S | 1 |
| Grootscholten, C | 1 |
| Derksen, RH | 1 |
| Berger, SP | 1 |
| de Sévaux, RG | 1 |
| Bijl, M | 1 |
| Berden, JH | 1 |
| Cabezuelo, JB | 1 |
| Egea, JP | 1 |
| Ramos, F | 1 |
| Torrella, E | 1 |
| Muray, S | 1 |
| Alcázar, C | 1 |
| Sokumbi, O | 1 |
| Wetter, DA | 1 |
| Makol, A | 1 |
| Warrington, KJ | 1 |
| Sundel, R | 1 |
| Solomons, N | 1 |
| Lisk, L | 1 |
| Miettunen, PM | 1 |
| Pistorio, A | 1 |
| Palmisani, E | 1 |
| Ravelli, A | 1 |
| Silverman, E | 1 |
| Oliveira, S | 1 |
| Alessio, M | 1 |
| Cuttica, R | 1 |
| Mihaylova, D | 1 |
| Espada, G | 1 |
| Pasic, S | 1 |
| Insalaco, A | 1 |
| Ozen, S | 1 |
| Porras, O | 1 |
| Sztajnbok, F | 1 |
| Lazarevic, D | 1 |
| Martini, A | 1 |
| Ruperto, N | 1 |
| Ayodele, OE | 1 |
| Okpechi, IG | 1 |
| Swanepoel, CR | 1 |
| Karim, MY | 1 |
| Alba, P | 1 |
| Cuadrado, MJ | 2 |
| Abbs, IC | 2 |
| D'Cruz, DP | 2 |
| Khamashta, MA | 1 |
| Hughes, GR | 2 |
| Shabtai, M | 1 |
| Ben-Haim, M | 1 |
| Zemer, D | 1 |
| Malinger-Saavedra, P | 1 |
| Rosin, D | 1 |
| Kuriansky, J | 1 |
| Lustig, S | 1 |
| Shabtai, EL | 1 |
| Shapira, Z | 1 |
| Ayalon, A | 1 |
| Gotti, E | 2 |
| Perico, N | 1 |
| Perna, A | 1 |
| Gaspari, F | 1 |
| Cattaneo, D | 1 |
| Caruso, R | 1 |
| Ferrari, S | 1 |
| Stucchi, N | 1 |
| Marchetti, G | 1 |
| Abbate, M | 1 |
| Remuzzi, G | 2 |
| Usta, M | 1 |
| Ersoy, A | 1 |
| Dilek, K | 1 |
| Ozdemir, B | 1 |
| Yavuz, M | 1 |
| Güllülü, M | 1 |
| Yurtkuran, M | 1 |
| Goumenos, DS | 2 |
| Davlouros, P | 2 |
| El Nahas, AM | 2 |
| Ahuja, M | 3 |
| Shortland, JR | 2 |
| Vlachojannis, JG | 1 |
| Brown, CB | 3 |
| Feehally, J | 1 |
| Bakker, RC | 1 |
| Hollander, AA | 1 |
| Mallat, MJ | 1 |
| Bruijn, JA | 1 |
| Paul, LC | 1 |
| de Fijter, JW | 1 |
| FIGUEROA, JE | 1 |
| NAKAMOTO, S | 1 |
| POUTASSE, EF | 1 |
| KOLFF, WJ | 1 |
| Korkmaz, C | 1 |
| Kabukcuoğlu, S | 1 |
| Isiksoy, S | 1 |
| Yalçin, AU | 1 |
| Czajkowski, K | 1 |
| Wójcicka-Bentyn, J | 1 |
| Sieńko, J | 1 |
| Grymowicz, M | 1 |
| Smolarczyk, R | 1 |
| Malinowska-Polubiec, A | 1 |
| Romejko, E | 1 |
| Mathieu, A | 1 |
| Grebe, SO | 1 |
| Mueller, TF | 1 |
| Troeltsch, M | 1 |
| Ebel, H | 1 |
| Lange, H | 1 |
| Shin, JI | 2 |
| Park, JM | 1 |
| Shin, YH | 1 |
| Kim, JH | 1 |
| Lee, JS | 2 |
| Kim, PK | 1 |
| Jeong, HJ | 2 |
| Pisoni, CN | 1 |
| Sanchez, FJ | 1 |
| Karim, Y | 1 |
| Khamasta, MA | 1 |
| van den Akker, JM | 1 |
| Wetzels, JF | 1 |
| Hoitsma, AJ | 2 |
| Kuhn, C | 1 |
| Kuhn, A | 1 |
| Markau, S | 1 |
| Kästner, U | 1 |
| Osten, B | 1 |
| Morales, J | 1 |
| Fierro, A | 1 |
| Benavente, D | 1 |
| Zehnder, C | 1 |
| Ferrario, M | 1 |
| Contreras, L | 1 |
| Herzog, C | 1 |
| Buckel, E | 1 |
| Cravedi, P | 1 |
| Costantini, M | 1 |
| Lesti, M | 1 |
| Ganeva, M | 1 |
| Gherardi, G | 1 |
| Ene-Iordache, B | 1 |
| Donati, D | 1 |
| Salvadori, M | 1 |
| Sandrini, S | 1 |
| Segoloni, G | 1 |
| Federico, S | 1 |
| Rigotti, P | 1 |
| Sparacino, V | 1 |
| Ruggenenti, P | 1 |
| Shenoy, M | 1 |
| Bradbury, MG | 1 |
| Lewis, MA | 1 |
| Webb, NJ | 1 |
| Doria, A | 1 |
| Alberighi, OD | 1 |
| Ferraccioli, G | 1 |
| Todesco, S | 1 |
| Manno, C | 1 |
| Altieri, P | 1 |
| Ferrara, R | 1 |
| Greco, S | 1 |
| Ponticelli, C | 2 |
| Castro, LA | 1 |
| Eigler, J | 1 |
| Land, W | 1 |
| Scholz, D | 1 |
| Hengst, P | 1 |
| Schilling, H | 1 |
| May, G | 1 |
| Schmitt, E | 1 |
| Mebel, M | 1 |
| Lee, HS | 1 |
| Mujais, SK | 1 |
| Kasinath, BS | 1 |
| Spargo, BH | 3 |
| Katz, AI | 1 |
| Brouhard, BH | 1 |
| Cunningham, RJ | 1 |
| Berger, M | 1 |
| Petrusick, TW | 1 |
| Travis, LB | 1 |
| Caspi, D | 1 |
| Fishel, R | 1 |
| Varon, M | 1 |
| Yona, E | 1 |
| Baratz, M | 1 |
| Yaron, M | 1 |
| Preuss, R | 1 |
| Riek, R | 1 |
| Steinhoff, J | 1 |
| Fricke, L | 1 |
| Hoyer, J | 1 |
| Sack, K | 1 |
| Nagao, T | 2 |
| Nagamatsu, T | 5 |
| Hilbrands, LB | 1 |
| Demacker, PN | 1 |
| Stalenhoef, AF | 1 |
| Koene, RA | 1 |
| Tanabe, K | 2 |
| Novick, AC | 2 |
| Streem, S | 1 |
| Hodge, E | 1 |
| McCauley, J | 1 |
| Shapiro, R | 1 |
| Jordan, M | 1 |
| Scantlebury, V | 1 |
| Vivas, C | 1 |
| Jensen, C | 1 |
| Starzl, TE | 1 |
| Thiel, G | 1 |
| Bock, A | 1 |
| Spöndlin, M | 1 |
| Brunner, FP | 1 |
| Mihatsch, M | 1 |
| Rufli, T | 1 |
| Landmann, J | 1 |
| Wilkie, ME | 1 |
| Beer, JC | 1 |
| Raftery, MJ | 1 |
| Dawnay, A | 1 |
| Barton, C | 1 |
| Marsh, FP | 1 |
| Chan, TM | 2 |
| Li, FK | 2 |
| Wong, RW | 1 |
| Wong, KL | 1 |
| Chan, KW | 2 |
| Cheng, IK | 1 |
| Yagisawa, T | 1 |
| Toma, H | 1 |
| Ota, K | 1 |
| Ishikawa, N | 1 |
| Tokumoto, N | 1 |
| Yaguchi, H | 1 |
| Nakada, T | 1 |
| Nagano, T | 1 |
| Uemura, T | 1 |
| Kanda, H | 1 |
| Akiyama, T | 1 |
| Kurita, T | 1 |
| Jindal, RM | 1 |
| Sidner, RA | 1 |
| Hughes, D | 1 |
| Pescovitz, MD | 1 |
| Leapman, SB | 1 |
| Milgrom, ML | 1 |
| Lumeng, L | 1 |
| Filo, RS | 1 |
| Hattori, T | 2 |
| Ito, M | 2 |
| Schiel, R | 1 |
| Bambauer, R | 1 |
| Latza, R | 1 |
| Klinkmann, J | 1 |
| Ghandour, FZ | 1 |
| Knauss, TC | 1 |
| Mulligan, DC | 1 |
| Schulak, JA | 1 |
| Hricik, DE | 1 |
| Bergstein, J | 1 |
| Leiser, J | 1 |
| Andreoli, SP | 1 |
| Brown, JH | 1 |
| Douglas, AF | 1 |
| Murphy, BG | 1 |
| Hill, CM | 1 |
| McNamee, PT | 1 |
| Nelson, WE | 1 |
| Doherty, CC | 1 |
| Kozłowska-Boszko, B | 1 |
| Durlik, M | 1 |
| Kuczyńska-Sicińska, J | 1 |
| Lao, M | 2 |
| Ito, H | 1 |
| Sakai, T | 1 |
| Takekoshi, Y | 1 |
| Awazu, M | 1 |
| Ito, K | 1 |
| Iitaka, K | 1 |
| Koitabashi, Y | 1 |
| Yamaoka, K | 1 |
| Nakagawa, K | 1 |
| Nakamura, H | 1 |
| Matsuyama, S | 1 |
| Seino, Y | 1 |
| Takeda, N | 1 |
| Hattori, S | 1 |
| Ninomiya, M | 1 |
| Goumenos, D | 1 |
| Gerakis, A | 1 |
| Hao, WK | 1 |
| Lui, SL | 1 |
| Tang, S | 1 |
| Lai, KN | 1 |
| Mastroianni Kirsztajn, G | 1 |
| Nishida, SK | 1 |
| Silva, MS | 1 |
| Ajzen, H | 1 |
| Pereira, AB | 1 |
| Kim, SC | 1 |
| Kang, CH | 1 |
| Kim, SK | 1 |
| Jang, HJ | 1 |
| Kim, TH | 1 |
| Jung, JG | 1 |
| Han, DJ | 1 |
| Nakache, R | 1 |
| Weinbroum, A | 1 |
| Merhav, H | 1 |
| Katz, P | 1 |
| Kaplan, E | 1 |
| Ballardie, FW | 1 |
| Roberts, ISD | 1 |
| Couser, WG | 1 |
| Stilmant, MM | 1 |
| Jermanovich, NB | 1 |
| Bürkle, PA | 1 |
| Tönnesmann, E | 1 |
| Franz, HE | 1 |
| Federlin, K | 1 |
| Kupor, LR | 1 |
| Lowance, DC | 1 |
| McPhaul, JJ | 1 |
| Hill, HF | 1 |
| Balsløv, JT | 2 |
| Brun, C | 5 |
| Jørgensen, F | 1 |
| Jørgensen, HE | 2 |
| Larsen, M | 3 |
| Larsen, S | 1 |
| Lorenzen, I | 5 |
| Thomsen, AC | 4 |
| Adeniyi, A | 2 |
| Hendrickse, RG | 2 |
| Soothill, JF | 1 |
| Cameron, JS | 8 |
| Appel, AE | 1 |
| Sablay, LB | 1 |
| Golden, RA | 1 |
| Barland, P | 1 |
| Grayzel, AI | 1 |
| Bank, N | 1 |
| Pap, I | 2 |
| Kemnitz, P | 1 |
| Willgeroth, Ch | 1 |
| Lagrue, G | 3 |
| Bernard, D | 1 |
| Bariety, J | 2 |
| Druet, P | 1 |
| Guenel, J | 1 |
| Feenstra, K | 1 |
| van den Lee, R | 1 |
| Greben, HA | 1 |
| Arends, A | 1 |
| Hoedemaeker, PJ | 1 |
| Zimmerman, SW | 1 |
| Jenkins, PG | 1 |
| Shelf, WD | 1 |
| Bloodworth, JM | 1 |
| Burkholder, PM | 2 |
| Pierce, JC | 1 |
| Kay, S | 1 |
| Lee, HM | 2 |
| Decker, JL | 1 |
| Klippel, JH | 1 |
| Plotz, PH | 1 |
| Steinberg, AD | 1 |
| Rahman, F | 1 |
| Zanger, B | 1 |
| Natelson, EA | 1 |
| Kuijten, RH | 1 |
| Donckerwolcke, RA | 1 |
| Tiddens, HA | 1 |
| Fonseca, JA | 1 |
| Ianhez, LE | 1 |
| Azevedo, LS | 1 |
| Sabbaga, E | 1 |
| Furuta, K | 1 |
| Hayashi, K | 1 |
| Brahm, M | 1 |
| Brammer, M | 1 |
| Gerstoft, J | 1 |
| Hayes, JM | 1 |
| Steinmuller, DR | 1 |
| Streem, SB | 1 |
| Ogawa, T | 1 |
| Inazu, M | 1 |
| Gotoh, K | 1 |
| Inoue, T | 1 |
| Hayashi, S | 1 |
| Banfi, G | 1 |
| Colturi, C | 1 |
| Montagnino, G | 1 |
| Widstam-Attorps, U | 1 |
| Bergström, J | 1 |
| Lefvert, AK | 1 |
| Appleby, P | 1 |
| Webber, DG | 1 |
| Bowen, JG | 1 |
| Schena, FP | 1 |
| Gärtner, U | 1 |
| Laurent, J | 1 |
| Belghiti, D | 1 |
| Adams, PL | 1 |
| Burkart, JM | 1 |
| Hamilton, RW | 1 |
| Lorentz, WB | 1 |
| Browning, MC | 1 |
| Meredith, JH | 1 |
| Heise, ER | 1 |
| Beaman, M | 1 |
| Howie, AJ | 1 |
| Hardwicke, J | 1 |
| Michael, J | 1 |
| Adu, D | 1 |
| Cade, R | 1 |
| Mars, D | 1 |
| Privette, M | 1 |
| Thompson, R | 1 |
| Croker, B | 1 |
| Peterson, J | 1 |
| Campbell, K | 1 |
| Glasgow, EF | 3 |
| Ogg, CS | 3 |
| White, RH | 4 |
| Boulton-Jones, M | 1 |
| Robinson, R | 1 |
| Ogg, C | 1 |
| Booth, LJ | 1 |
| Aber, GM | 1 |
| Busch, GJ | 1 |
| Galvanek, EG | 1 |
| Reynolds, ES | 1 |
| Mukherjee, AP | 1 |
| Diekmann, L | 1 |
| Hüther, W | 1 |
| Manitz, G | 1 |
| Mönninghoff, W | 1 |
| McIntosh, RM | 2 |
| Griswold, W | 1 |
| Smith, FG | 1 |
| Kaufman, DB | 1 |
| Urizar, R | 1 |
| Vernier, RL | 3 |
| Hayslett, JP | 2 |
| Kashgarian, M | 2 |
| Cook, CD | 1 |
| Hermann, G | 1 |
| Zühlke, V | 1 |
| Faul, P | 1 |
| Asamer, H | 1 |
| Michael, AF | 1 |
| Drummond, KN | 3 |
| Levitt, JI | 2 |
| Herdman, RC | 1 |
| Fish, AJ | 1 |
| Good, RA | 2 |
| Harlan, WR | 1 |
| Holden, KR | 1 |
| Williams, GM | 2 |
| Hume, DM | 2 |
| Shorter, RG | 1 |
| Hallenbeck, GA | 1 |
| Nava, C | 1 |
| O'Kane, H | 1 |
| DeWeerd, JH | 1 |
| Johnson, WJ | 1 |
| Feizi, T | 1 |
| Gitlin, N | 1 |
| Houba, V | 1 |
| Mills, RJ | 1 |
| Wildhirt, E | 1 |
| Claman, HN | 1 |
| Karr, RM | 1 |
| Kohler, PF | 1 |
| Mass, MF | 1 |
| Sams, WM | 1 |
| Small, P | 1 |
| Stanford, RE | 1 |
| Thorne, EG | 1 |
| Forbes, MJ | 1 |
| Sinclair, L | 1 |
| Jensen, H | 1 |
| Olgaard, K | 1 |
| Faarup, P | 1 |
| Krumlovsky, FA | 1 |
| Del Greco, F | 1 |
| Herdson, PB | 1 |
| Lazar, P | 1 |
| Berry, H | 1 |
| Huskisson, EC | 1 |
| Laver, MC | 1 |
| Kincaid-Smith, P | 2 |
| Gabriel, R | 1 |
| Meadow, SR | 1 |
| Moncrieff, MW | 1 |
| Zech, P | 2 |
| Richard, P | 1 |
| Blanc-Brunat, N | 1 |
| Labeeuw, M | 1 |
| Colon, S | 1 |
| Pozet, N | 1 |
| Dupont, E | 1 |
| Fries, D | 2 |
| Traeger, J | 2 |
| Arieff, AI | 1 |
| Pinggera, WF | 1 |
| Wing, AJ | 1 |
| Hutt, MS | 1 |
| Kibukamusoke, JW | 2 |
| Seigler, HF | 1 |
| Gunnells, JC | 1 |
| Robinson, RR | 1 |
| Ward, FE | 1 |
| Amos, DB | 1 |
| Rowlands, DT | 1 |
| Klein, WJ | 1 |
| Stickel, DL | 1 |
| Wallnöfer, H | 1 |
| Hanusch, M | 1 |
| Horbach, J | 1 |
| van Liebergen, F | 1 |
| Mastboom, J | 1 |
| Wijdeveld, P | 1 |
| Linshaw, MA | 1 |
| Gruskin, AB | 1 |
| Barnes, AD | 1 |
| Coles, GA | 1 |
| White, HJ | 1 |
| Ljunghall, S | 1 |
| Fjellström, KE | 1 |
| Wibell, L | 1 |
| Tessmann, D | 1 |
| Schill, H | 1 |
| Voss, J | 1 |
| Hamann, H | 1 |
| Engelmann, C | 1 |
| Skinhoj, P | 1 |
| Steiness, I | 1 |
| Gömöri, P | 1 |
| Beregi, E | 1 |
| Varga, S | 1 |
| Orlowski, T | 1 |
| Gradowska, L | 1 |
| Rancewicz, Z | 1 |
| Rowinska, D | 1 |
| Alatas, H | 1 |
| Wirja, IG | 1 |
| Bensch, KG | 1 |
| Freedman, LR | 1 |
| Epstein, FH | 1 |
| Balslov, JT | 3 |
| Jensen, KB | 3 |
| Jorgensen, F | 3 |
| Jorgensen, HE | 3 |
| Nanra, RS | 1 |
| Hurley, RM | 2 |
| Makker, SP | 1 |
| Heymann, W | 1 |
| Bruna-Blanc, N | 1 |
| Banssillon, V | 1 |
| Touboul, P | 1 |
| Canarelli, G | 1 |
| Ginn, HE | 1 |
| Sharpstone, P | 1 |
| Urizar, RE | 1 |
| Tinglof, B | 1 |
| McIntosh, R | 1 |
| Litman, N | 1 |
| Barnett, E | 1 |
| Wilkerson, J | 1 |
| Smith, F | 1 |
| Hansson, L | 1 |
| Berglund, G | 1 |
| Vikgren, P | 1 |
| Najarian, JS | 2 |
| Foker, JE | 1 |
| Rossipal, E | 1 |
| Brass, H | 3 |
| Lapp, H | 1 |
| Heintz, R | 1 |
| Gewurz, H | 1 |
| Pickering, RJ | 1 |
| Moberg, A | 1 |
| Simmons, RL | 1 |
| Wilbrandt, R | 1 |
| Frotscher, U | 1 |
| Freyland, M | 1 |
| Messerschmidt, W | 1 |
| Richter, R | 1 |
| Schulte-Lippern, M | 1 |
| Zschaege, B | 1 |
| Ahlmén, J | 1 |
| Attman, PO | 1 |
| Bengtsson, YU | 1 |
| Lynfield, YL | 1 |
| Prestia, AE | 1 |
| Miller, WE | 1 |
| Vidt, DG | 1 |
| Deodhar, SD | 1 |
| Gifford, RW | 1 |
| Humphrey, DC | 1 |
| Maher, JF | 1 |
| Schreiner, GE | 1 |
| Kaplan, NG | 1 |
| Kaplan, KC | 1 |
| McDonald, R | 1 |
| Thomsen, A | 1 |
| Kämpfen, P | 1 |
| Hodler, J | 1 |
| Mehls, O | 1 |
| Schärer, K | 1 |
| O'Dwyer, WF | 1 |
| Bianchessi, M | 1 |
| Porro, GB | 1 |
| Tagliabue, M | 1 |
| Trounce, JR | 1 |
| Guisan, M | 1 |
| Bircher, J | 1 |
| Kistler, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis[NCT00371319] | Phase 4 | 150 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Randomized Multicenter Trial Comparing Mycophenolate Mofetil and Azathioprine as Remission-maintaining Treatment for Proliferative Lupus Glomerulonephritis. The MAINTAIN Nephritis Trial.[NCT00204022] | Phase 3 | 105 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis[NCT00307645] | Phase 3 | 160 participants | Interventional | 2003-05-31 | Terminated | ||
| A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.[NCT00377637] | Phase 3 | 370 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy[NCT00367562] | Phase 4 | 20 participants | Interventional | 1996-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Treatment Failure was adjudicated by a clinical endpoints committee (CEC) and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis (LN). (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | Deaths (Number) |
|---|---|
| Mycophenolate Mofetil (MMF) | 0 |
| Azathioprine (AZA) | 1 |
Time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), was defined as any 1 the following: death, ESRD, sustained doubling of serum creatinine, renal flare (proteinuric or nephritic), or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. ESRD is defined as progression to chronic hemodialysis or renal transplant. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | participants (Number) |
|---|---|
| Mycophenolate Mofetil (MMF) | 0 |
| Azathioprine (AZA) | 3 |
Sustained doubling of serum creatinine concentration is defined as the first serum creatinine value that is twice the mean of the lowest 2 values from screening to end of induction, as confirmed by a second serum creatinine value obtained at least 4 weeks after the initial doubling. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | participants (Number) |
|---|---|
| Mycophenolate Mofetil | 1 |
| Azathioprine | 5 |
A major extra-renal flare is defined as a British Isles Lupus Assessment Group (BILAG) Score category A in one extrarenal organ or three organs with concurrent category B scores. BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | participants (Number) |
|---|---|
| Mycophenolate Mofetil | 7 |
| Azathioprine | 6 |
The SF-36 is a 36 item quality of life questionnaire. The short-form version has eleven questions that permit the participant to rate how they feel that particular day. The SF-36 consists of eight scaled scores and two component scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score with the higher scores indicating better quality of life. (NCT00377637)
Timeframe: Baseline and 24 weeks
| Intervention | Scores on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Physical Component Summary [n=139, 137] | Mental Component Summary [n=139, 137] | Bodily Pain Score [n=141, 137] | General Health Score [n=139, 137] | Mental Health Score [n=141, 137] | Physical functioning Score [n=141, 137] | Role-Emotional Score [n=141, 137] | Role-Physical Score [n=141, 137] | Social Function Score [n=141, 137] | Vitality Score [n=141, 137] | |
| Intravenous Cyclophosphamide | 6.4 | 5.7 | 16.8 | 11.5 | 9.8 | 9.3 | 18.4 | 34.0 | 18.2 | 11.6 |
| Mycophenolate Mofetil | 5.2 | 6.7 | 13.4 | 9.1 | 9.3 | 11.6 | 23.4 | 28.6 | 17.7 | 14.2 |
24-hour urine protein was measured at Baseline and Week 24. (NCT00377637)
Timeframe: Baseline, Week 24
| Intervention | mg/day (Mean) | ||
|---|---|---|---|
| Baseline [n=180, 180] | Week 24 [n= 150, 144] | Change from Baseline to Week 24 [n= 146, 142] | |
| Intravenous Cyclophosphamide | 4451.4 | 1831.6 | -2513.7 |
| Mycophenolate Mofetil | 4208.9 | 1599.0 | -2510.6 |
(NCT00377637)
Timeframe: Baseline, Week 24
| Intervention | g/L (Mean) | ||
|---|---|---|---|
| Baseline [n=184, 185] | Week 24 [n=155, 151] | Change from Baseline to Week 24 [n=154, 151] | |
| Intravenous Cyclophosphamide | 28.6 | 38.3 | 9.0 |
| Mycophenolate Mofetil | 30.5 | 38.4 | 7.5 |
(NCT00377637)
Timeframe: Baseline, Week 24
| Intervention | µmol/L (Mean) | ||
|---|---|---|---|
| Baseline [n= 184, 185] | Week 24 [n= 155, 151] | Change from Baseline to Week 24 [n= 154, 151] | |
| Intravenous Cyclophosphamide | 92.7 | 83.5 | -5.1 |
| Mycophenolate Mofetil | 108.6 | 77.6 | -18.9 |
"BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. The BILAG individual system summaries were calculated by a program supplied by ADS-Limathon (Sheffield, UK).~The score at baseline was compared to the score at the 24 week endpoint for each treatment group, reported here for the renal system." (NCT00377637)
Timeframe: Baseline, 24 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shift from Baseline=A to 24 Week Endpoint=A | Shift from Baseline=A to 24 Week Endpoint=B | Shift from Baseline=A to 24 Week Endpoint=C | Shift from Baseline=A to 24 Week Endpoint=D | Shift from Baseline=B to 24 Week Endpoint=A | Shift from Baseline=B to 24 Week Endpoint=B | Shift from Baseline=B to 24 Week Endpoint=C | Shift from Baseline=B to 24 Week Endpoint=D | Shift from Baseline=C to 24 Week Endpoint=A | Shift from Baseline=C to 24 Week Endpoint=B | Shift from Baseline=C to 24 Week Endpoint=C | Shift from Baseline=C to 24 Week Endpoint=D | Shift from Baseline=D to 24 Week Endpoint=A | Shift from Baseline=D to 24 Week Endpoint=B | Shift from Baseline=D to 24 Week Endpoint=C | Shift from Baseline=D to 24 Week Endpoint=D | |
| Intravenous Cyclophosphamide | 27.1 | 34.8 | 24.9 | 9.4 | 0.0 | 1.1 | 1.7 | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 |
| Mycophenolate Mofetil | 17.1 | 39.2 | 33.1 | 5.5 | 0.0 | 1.7 | 2.2 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Number of participants achieving complete remission as defined by return to normal serum creatinine, proteinuria ≤500 mg/24 hours and an inactive urinary sediment (absence of red blood cells, white blood cells or cellular or granular casts) after 24 weeks. (NCT00377637)
Timeframe: 24 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Complete Remission - Yes | Complete Remission - No | |
| Intravenous Cyclophosphamide | 15 | 170 |
| Mycophenolate Mofetil | 16 | 169 |
Treatment response was adjudicated by a blinded clinical endpoints committee (CEC) and defined as: a) Decrease in proteinuria, defined as a decrease in the urine protein to creatinine ratio (UPCr) to <3 in subjects with baseline proteinuria ≥3 UPCr or a decrease in the UPCr by ≥50% in subjects with proteinuria <3 UPCr at Baseline, and b) Stabilization of serum creatinine or improvement. UPCr were derived from the 24 hour urine collection. Patients who did not show a treatment response at Week 24 or who withdrew earlier than Week 24 were considered non-responders. (NCT00377637)
Timeframe: 24 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Non-responder | |
| Intravenous Cyclophosphamide | 98 | 87 |
| Mycophenolate Mofetil | 104 | 81 |
The primary efficacy parameter was the time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), defined as any of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to rescue treatment for each patient. The data presented are the percentage of participants who were rescue treatment free at each time interval as estimated by Kaplan-Meier. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Start of Maintenance Phase to Month 3 | Month 3 to Month 6 | Month 6 to Month 9 | Month 9 to Month 12 | Month 12 to Month 15 | Month 15 to Month 18 | Month 18 to Month 21 | Month 21 to Month 24 | Month 24 to Month 27 | Month 27 to Month 30 | Month 30 to Month 33 | Month 33 to Month 36 | |
| Azathioprine | 99.1 | 95.1 | 93.0 | 91.9 | 88.4 | 87.1 | 83.1 | 83.1 | 81.7 | 80.3 | 78.8 | 75.9 |
| Mycophenolate Mofetil | 100 | 98.2 | 97.2 | 94.2 | 94.2 | 94.2 | 93.1 | 91.9 | 90.8 | 90.8 | 90.8 | 90.8 |
A proteinuric flare is defined as a doubling of the urine protein:creatinine ratio, and proteinuria ≥1 g/24 h in patients with urine protein ≤0.5 g/24 h at the end of the induction phase, or proteinuria ≥2 g/24 h if urine protein was >0.5 g/24 h at the end of the induction phase. A nephritic flare is defined as a 25% increase in serum creatinine accompanied by 1 or more of the following: (a) simultaneous doubling of the proteinuria reaching a minimum of 2 g/24 h (b) new/increased hematuria or (c) the appearance of cellular casts. All flares were adjudicated by a clinical endpoints committee. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Start of Maintenance Phase to Month 3 | Month 3 to Month 6 | Month 6 to Month 9 | Month 9 to Month 12 | Month 12 to Month 15 | Month 15 to Month 18 | Month 18 to Month 21 | Month 21 to Month 24 | Month 24 to Month 27 | Month 27 to Month 30 | Month 30 to Month 33 | Month 33 to Month 36 | |
| Azathioprine | 97.2 | 90.3 | 87.2 | 85.0 | 82.8 | 79.2 | 78.0 | 75.5 | 74.2 | 74.2 | 72.9 | 70.1 |
| Mycophenolate Mofetil | 98.2 | 94.6 | 90.8 | 87.8 | 87.8 | 86.8 | 86.8 | 86.8 | 86.8 | 86.8 | 85.6 | 85.6 |
Treatment Failure was adjudicated by a clinical endpoints committee and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to treatment failure for each patient. The data presented are the percentage of participants who were treatment-failure free at each time interval as estimated by Kaplan-Meier. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Start of Maintenance Phase to Month 3 | Month 3 to Month 6 | Month 6 to Month 9 | Month 9 to Month 12 | Month 12 to Month 15 | Month 15 to Month 18 | Month 18 to Month 21 | Month 21 to Month 24 | Month 24 to Month 27 | Month 27 to Month 30 | Month 30 to Month 33 | Month 33 to Month 36 | |
| Azathioprine | 97.2 | 89.3 | 86.2 | 83.0 | 77.5 | 74.1 | 70.7 | 68.3 | 67.1 | 65.9 | 63.4 | 58.6 |
| Mycophenolate Mofetil | 98.2 | 93.7 | 89.9 | 86.0 | 86.0 | 84.9 | 84.9 | 83.9 | 82.8 | 82.8 | 81.7 | 81.7 |
9 reviews available for azathioprine and Proteinuria
| Article | Year |
|---|---|
Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Drug Therapy, Combination; Female; Follow-Up Studies; | 2016 |
Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Azathioprine; Child; Child, Preschool; Cycloph | 2010 |
Long-term results of a randomized controlled trial in childhood IgA nephropathy.
Topics: Adolescent; Anticoagulants; Azathioprine; Cell Proliferation; Child; Dipyridamole; Disease Progressi | 2011 |
[After care of kidney transplant patients].
Topics: Adrenal Cortex Hormones; Aftercare; Antilymphocyte Serum; Azathioprine; Cyclosporins; Graft Rejectio | 1983 |
Immunosuppressive agents in the treatment of the nephrotic syndrome and glomerulonephritis in children.
Topics: Azathioprine; Child; Chlorambucil; Cyclophosphamide; Glomerulonephritis; Humans; Immunosuppressive A | 1979 |
Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective survey.
Topics: Azathioprine; Cyclophosphamide; Glomerulonephritis; Humans; Prednisone; Proteinuria; Retrospective S | 1988 |
Management of the nephrotic syndrome.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Chlorambucil; Clinical Trials as Topic; Cyclophos | 1974 |
Late medical complications of renal transplantation.
Topics: Adrenal Cortex Hormones; Adult; Allopurinol; Autoimmune Diseases; Azathioprine; Bone Diseases; Diabe | 1969 |
Immunosuppressant agents in the treatment of glomerulonephritis. 2. Cytotoxic drugs.
Topics: Adult; Anti-Glomerular Basement Membrane Disease; Antilymphocyte Serum; Antineoplastic Agents; Azath | 1971 |
44 trials available for azathioprine and Proteinuria
| Article | Year |
|---|---|
Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.
Topics: Adult; Azathioprine; Blood Pressure; Brazil; Drug Therapy, Combination; Female; Humans; Immunosuppre | 2018 |
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Creatinine; Disease Progression; Drug Therapy, Combin | 2016 |
Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.
Topics: Adult; Azathioprine; Disease Progression; Female; Follow-Up Studies; Humans; Immunosuppressive Agent | 2016 |
Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Creatinine; Drug Therapy, Combinatio | 2016 |
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, C | 2010 |
Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Antihypertensive Agents; Azathioprine; Blood Pressure; Drug Therapy, | 2010 |
Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Azathioprine; Cyclophosphamide; Female; Glomerular Filtration Rat | 2010 |
Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study.
Topics: Adult; Azathioprine; Cyclosporine; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Humans | 2011 |
Long-term results of a randomized controlled trial in childhood IgA nephropathy.
Topics: Adolescent; Anticoagulants; Azathioprine; Cell Proliferation; Child; Dipyridamole; Disease Progressi | 2011 |
Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Azathioprine; Creatinine; Cyclophosphamide; Female; Fol | 2012 |
Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial.
Topics: Administration, Oral; Adolescent; Age Factors; Asia; Azathioprine; Biomarkers; Creatinine; Cyclophos | 2012 |
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents.
Topics: Adult; Antibodies, Antinuclear; Azathioprine; Cyclophosphamide; Female; Follow-Up Studies; Humans; I | 2002 |
Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings.
Topics: Adult; Azathioprine; Biopsy; Calcineurin Inhibitors; Chronic Disease; Cyclosporine; Drug Therapy, Co | 2003 |
Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment.
Topics: Adrenal Cortex Hormones; Adult; Antihypertensive Agents; Azathioprine; Blood Pressure; Cyclophospham | 2003 |
Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.
Topics: Adult; Azathioprine; Biopsy; Cardiovascular Diseases; Cause of Death; Chronic Disease; Cyclosporine; | 2003 |
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Follow- | 2004 |
Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.
Topics: Aged; Azathioprine; Calcineurin Inhibitors; Carcinoma, Squamous Cell; Creatinine; Female; Follow-Up | 2006 |
Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
Topics: Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Azathioprine; Basiliximab; Calcineurin Inhibitor | 2007 |
Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
Topics: Adult; Azathioprine; Female; Follow-Up Studies; Glomerular Filtration Rate; Graft Rejection; Humans; | 2007 |
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
Topics: Administration, Oral; Adult; Azathioprine; Complement C3; Complement C4; Creatinine; Cyclophosphamid | 2006 |
The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients.
Topics: Adult; Apolipoproteins; Arteriosclerosis; Azathioprine; Cholesterol, HDL; Cyclosporine; Female; Graf | 1995 |
Long-term benefits and risks of cyclosporin A (sandimmun)--an analysis at 10 years.
Topics: Antihypertensive Agents; Azathioprine; Blood Pressure; Cadaver; Creatinine; Cyclosporine; Drug Thera | 1994 |
Effect of nifedipine on renal haemodynamics and urinary protein excretion in stable renal transplant recipients.
Topics: Adult; Azathioprine; Blood Pressure; Creatinine; Cyclosporine; Female; Follow-Up Studies; Glomerular | 1993 |
Cyclosporine and therapeutic plasma exchange in treatment of progressive autoimmune diseases.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibody Formation; Azathioprine; Behcet Syndrome; Combined Mo | 1997 |
Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Creatinine; Drug Therapy, Combination; Female; Gl | 1998 |
Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone.
Topics: Adolescent; Adult; Aged; Azathioprine; Disease Progression; Female; Glomerulonephritis, Membranous; | 1998 |
A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.
Topics: Adolescent; Azathioprine; Blood Urea Nitrogen; Child; Dipyridamole; Drug Therapy, Combination; Glome | 1999 |
Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression.
Topics: Adult; Alopecia; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Cyclophosphamide; Drug Ther | 1999 |
Urinary retinol-binding protein as a prognostic marker in the treatment of nephrotic syndrome.
Topics: Adolescent; Adult; Azathioprine; Biomarkers; Child; Creatinine; Cyclophosphamide; Cyclosporine; Fema | 2000 |
Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization.
Topics: Azathioprine; Biopsy; Blood Pressure; Cholesterol; Creatinine; Cyclosporine; Drug Therapy, Combinati | 2001 |
Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.
Topics: Adult; Azathioprine; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Erythr | 2002 |
Treatment of rheumatoid arthritis with penicillamine.
Topics: Arthritis, Rheumatoid; Azathioprine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dru | 1977 |
Cytostatic treatment of glomerular diseases. IV. The effect of combined immunosuppressive treatment on serum creatinine and proteinuria evaluated by sequential statistical analysis. Report from a Copenhagen study group of renal diseases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Azathioprine; Child; Clinical Trials as Topic; Creat | 1978 |
A controlled trial of cyclophosphamide and azathioprine in Nigerian children with the nephrotic syndrome and poorly selective proteinuria.
Topics: Azathioprine; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Female; Follow-Up | 1979 |
[Treatment with chlorambucil and azathioprine in primary glomerulonephritis. Results of a "controlled" study].
Topics: Anti-Bacterial Agents; Antihypertensive Agents; Azathioprine; Chlorambucil; Clinical Trials as Topic | 1975 |
Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis.
Topics: Adolescent; Adult; Aged; Azathioprine; Blood Urea Nitrogen; Clinical Trials as Topic; Female; Glomer | 1976 |
Progression from minimal or focal to diffuse proliferative lupus nephritis.
Topics: Adolescent; Adult; Azathioprine; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Glomerul | 1975 |
Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months.
Topics: Adolescent; Adult; Amenorrhea; Azathioprine; Child; Clinical Trials as Topic; Complement C3; Cycloph | 1975 |
Immunosuppressive therapy in adults with proliferative glomerulonephritis. Controlled trial.
Topics: Adolescent; Adult; Azathioprine; Biopsy; Blood Pressure; Clinical Trials as Topic; Creatinine; Cyclo | 1970 |
Selectivity of proteinuria and response to prednisolone or immunosuppressive drugs in children with malarial nephrosis.
Topics: Albuminuria; Azathioprine; Biopsy; Child; Complement System Proteins; Cyclophosphamide; Female; Fluo | 1970 |
[Treatment of chronic hepatitis with immunosuppressive agents and D-penicillamine].
Topics: Agranulocytosis; Azathioprine; Chronic Disease; Clinical Trials as Topic; Drug Hypersensitivity; Fem | 1973 |
Management of the nephrotic syndrome.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Chlorambucil; Clinical Trials as Topic; Cyclophos | 1974 |
Nephrotic syndrome due to primary renal disease in adults: II. A controlled trial of prednisolone and azathioprine.
Topics: Adolescent; Adult; Aged; Azathioprine; Clinical Trials as Topic; Creatinine; Drug Synergism; Female; | 1969 |
Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party.
Topics: Adolescent; Adult; Age Factors; Azathioprine; Child; Chronic Disease; Clinical Trials as Topic; Crea | 1971 |
151 other studies available for azathioprine and Proteinuria
| Article | Year |
|---|---|
Fibrillar glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis.
Topics: Azathioprine; Female; Glomerulonephritis; HSP40 Heat-Shock Proteins; Humans; Lupus Erythematosus, Sy | 2023 |
Predictors of treatment outcomes in lupus nephritis with severe acute kidney injury and requirement of dialytic support.
Topics: Acute Kidney Injury; Azathioprine; Humans; Kidney; Lupus Nephritis; Proteinuria; Renal Dialysis; Ret | 2023 |
Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center.
Topics: Adult; Azathioprine; Biopsy; Complement C3; Complement C4; Creatinine; Cyclophosphamide; Delayed Dia | 2020 |
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Topics: Antirheumatic Agents; Azathioprine; Calcineurin Inhibitors; Drug Therapy, Combination; Europe; Glome | 2020 |
[Idiopathic nephrotic syndrome (INS) in children in Dakar: about 40 cases].
Topics: Azathioprine; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Female; Glucocorticoid | 2017 |
The profile and clinical outcomes of patients with renal involvement due to IgA vasculitis: is azathioprine a good option for treatment?
Topics: Adolescent; Antirheumatic Agents; Azathioprine; Child; Child, Preschool; Cyclophosphamide; Female; H | 2019 |
Nationwide survey on current treatments for IgA nephropathy in Japan.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Azathioprine; Chi | 2013 |
Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Azathioprine; Biomarkers; Biopsy; Creatinine; Cytokin | 2013 |
Granulomatosis with polyangiitis presenting as Henoch-Schönlein purpura in children.
Topics: Abdominal Pain; Anti-Infective Agents; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Child; | 2013 |
Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor.
Topics: Adult; Aged; Allografts; Antibodies, Monoclonal; Azathioprine; Basiliximab; BK Virus; Cohort Studies | 2014 |
Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Topics: Adult; Azathioprine; Biomarkers; Calcineurin Inhibitors; Creatinine; Cytomegalovirus Infections; Fem | 2013 |
A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link.
Topics: Adult; alpha-Galactosidase; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, | 2014 |
Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study.
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Stud | 2015 |
Necrotizing crescentic glomerulonephritis related to sarcoidosis: a case report.
Topics: Adult; Azathioprine; Black or African American; Creatinine; Female; Foot Diseases; Glomerulonephriti | 2015 |
Liver transplant alone without kidney transplant for fibrinogen Aα-chain (AFib) renal amyloidosis.
Topics: Amyloidosis; Azathioprine; Creatinine; Female; Fibrinogen; Gene Expression; Genes, Dominant; Graft v | 2016 |
Effective treatment with azathioprine for renal amyloidosis secondary to familial Mediterranean fever.
Topics: Adult; Amyloidosis; Azathioprine; Blood Sedimentation; C-Reactive Protein; Creatinine; Familial Medi | 2016 |
Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study.
Topics: Adolescent; Adrenal Cortex Hormones; Age Distribution; Antibodies, Antineutrophil Cytoplasmic; Asia; | 2016 |
Early initiation of immunosuppressive treatment in membranous nephropathy patients.
Topics: Adult; Aged; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Glomer | 2017 |
[Crohn's disease in association with IgA nephropathy].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antimetabo | 2008 |
Immunosuppression improves blood pressure and endothelial function in a rat model of pregnancy-induced hypertension.
Topics: Animals; Azathioprine; Blood Pressure; Cytokines; Desoxycorticosterone; Disease Models, Animal; Endo | 2009 |
Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option.
Topics: Administration, Oral; Adult; Aged; Azathioprine; Black People; Creatinine; Cyclophosphamide; Female; | 2009 |
Graves' disease associated with primary systemic sclerosis.
Topics: Azathioprine; Bosentan; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Graves | 2009 |
Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis.
Topics: Adult; Azathioprine; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonephr | 2011 |
Protein-losing enteropathy as initial manifestation of systemic lupus erythematosus.
Topics: Adolescent; Antibodies, Antinuclear; Azathioprine; Biomarkers; Complement C3; Diarrhea; Drug Therapy | 2012 |
Infliximab in the treatment of amyloidosis secondary to Crohn's disease.
Topics: Adult; Amyloidosis; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Deglutition Disorders; Drug | 2012 |
Vasculitis associated with tumor necrosis factor-α inhibitors.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2012 |
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study.
Topics: Adolescent; Age of Onset; Azathioprine; Cohort Studies; Cyclophosphamide; Drug Therapy, Combination; | 2013 |
Long-term renal outcome and complications in South Africans with proliferative lupus nephritis.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Blood Pressure; Creatinine; Cyclophosphamide; Disease | 2013 |
Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Azathioprine; Colchicine; Creatinine; Cyclosporine; | 2002 |
Prednisolone and azathioprine in IgA nephropathy - a ten-year follow-up study.
Topics: Adult; Azathioprine; Comorbidity; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up St | 2003 |
Treating IgA Nephropathy - Who, When and How?.
Topics: Adrenal Cortex Hormones; Adult; Angiotensin-Converting Enzyme Inhibitors; Azathioprine; Cyclophospha | 2003 |
RENAL HOMOTRANSPLANTATION IN MAN; REPORT OF SIX CONSECUTIVE CASES.
Topics: Adolescent; Anuria; Azathioprine; Blood Chemical Analysis; Dactinomycin; Drug Therapy; Hypertension; | 1964 |
Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Azathioprine; Female; Glomeruloscler | 2003 |
Renal function and lipid metabolism in pregnant renal transplant recipients.
Topics: Acidosis; Adult; Azathioprine; Chlorides; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinin | 2004 |
Effect of mycophenolate mofetil on kidney graft function and body weight in patients with chronic allograft nephropathy.
Topics: Albuminuria; Azathioprine; Body Weight; Creatinine; Cyclosporine; Drug Therapy, Combination; Graft S | 2004 |
Can azathioprine and steroids alter the progression of severe Henoch-Schönlein nephritis in children?
Topics: Adolescent; Azathioprine; Biopsy; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination | 2005 |
Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.
Topics: Adult; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Kidney; Lupus Nephr | 2005 |
Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study.
Topics: Adult; Aged; Azathioprine; Creatinine; Drug Therapy, Combination; Female; Follow-Up Studies; Glomeru | 2006 |
Effect of immunoadsorption on refractory idiopathic focal and segmental glomerulosclerosis.
Topics: Adult; Anemia, Megaloblastic; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Azathioprine and tubulointerstitial nephritis in HSP.
Topics: Azathioprine; Child; Contraindications; Humans; IgA Vasculitis; Immunosuppressive Agents; Kidney; Ne | 2006 |
Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression.
Topics: Adolescent; Adrenal Cortex Hormones; Age of Onset; Azathioprine; Child; Cyclophosphamide; Female; Fo | 2007 |
[Pregnancy after kidney transplantation. Report of 6 successful cases with multiple risk factors].
Topics: Adolescent; Adult; Azathioprine; Birth Weight; Blood Pressure; Creatinine; Female; Humans; Immunosup | 1983 |
Course of renal pathology in patients with systemic lupus erythematosus.
Topics: Adult; Azathioprine; Biopsy; Blood Pressure; Creatinine; Cyclophosphamide; Female; Follow-Up Studies | 1984 |
Urinary kallikrein excretion in renal transplant patients.
Topics: Adolescent; Azathioprine; Child; Female; Graft Rejection; Humans; Kallikreins; Kidney Transplantatio | 1982 |
Multisystem presentation of eosinophilic fasciitis.
Topics: Adult; Ankle Joint; Azathioprine; Blood Sedimentation; Bone Marrow Examination; Elbow Joint; Eosinop | 1982 |
Does alpha 1 microglobulin in urine predict renal function after transplantation?
Topics: Albuminuria; Alpha-Globulins; Azathioprine; Biomarkers; Creatinine; Cyclosporine; Drug Therapy, Comb | 1994 |
Effect of DP-1904, a thromboxane A2 synthase inhibitor, administered from the autologous phase on crescentic-type anti-GBM nephritis in rats.
Topics: Animals; Antimetabolites; Azathioprine; Creatinine; Enzyme Inhibitors; gamma-Globulins; Glomerulonep | 1995 |
Long-term renal function in cyclosporine-treated renal allograft recipients.
Topics: Adult; Azathioprine; Chi-Square Distribution; Creatinine; Cyclosporine; Female; Graft Rejection; Hum | 1995 |
FK 506 in the management of nephrotic syndrome after renal transplantation.
Topics: Azathioprine; Biopsy; Creatinine; Cyclosporine; Graft Rejection; Humans; Kidney Transplantation; Nep | 1993 |
Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone.
Topics: Adult; Azathioprine; Cohort Studies; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Female | 1995 |
Early steroid withdrawal after kidney transplantation.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Azathioprine; CD4-CD8 Ratio; Cholesterol; Cholesterol, | 1996 |
Effects of deoxyspergualine on chronic transplant nephropathy.
Topics: Azathioprine; Biomarkers; Chronic Disease; Creatinine; Cyclosporine; Drug Therapy, Combination; Fema | 1996 |
Metabolic problems in recipients of liver transplants.
Topics: Adult; Azathioprine; Carbohydrate Metabolism; Creatinine; Cyclosporine; Diabetes Mellitus; Female; F | 1996 |
The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats.
Topics: Animals; Anticholesteremic Agents; Azathioprine; CD4-Positive T-Lymphocytes; Cholestyramine Resin; C | 1996 |
Effect of DP-1904, a thromboxane A2 synthase inhibitor, on passive Heymann nephritis in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Antibodies; Azathioprine; Creatinine; Dinoprostone; Drug Inte | 1996 |
Influence of steroid withdrawal on proteinuria in renal allograft recipients.
Topics: Acute Disease; Analysis of Variance; Anti-Inflammatory Agents; Azathioprine; Chi-Square Distribution | 1997 |
Predictor of transplanted kidney deterioration following pregnancy--daily urine protein loss or serum creatinine concentration?
Topics: Adolescent; Adult; Azathioprine; Biomarkers; Creatinine; Cyclosporine; Drug Therapy, Combination; Fe | 1996 |
Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy?
Topics: Adult; Aged; Azathioprine; Biopsy; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Humans | 1999 |
Impact of heavy proteinuria (>1 g/d) following renal transplantation.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Azathioprine; Biomarkers; Child; Cyclos | 2000 |
Complement-independent nephrotoxic nephritis in the guinea pig.
Topics: Animals; Antibodies; Aprotinin; Azathioprine; Basement Membrane; Colchicine; Complement System Prote | 1977 |
[Mesangiocapillary glomerulonephritis and rheumatoid arthritis. A case with diagnostic and therapeutic questions (author's transl)].
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Beta-Globulins; Complement C3; Complement C4; Complement | 1976 |
Single and multiple drug therapy in autologous immune complex nephritis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azathioprine; Basement Membrane; Compleme | 1976 |
The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis: a two year prospective study.
Topics: Antibodies; Azathioprine; Complement System Proteins; DNA; Humans; Kidney Glomerulus; Lupus Erythema | 1978 |
[Monitoring of the clinical and morphological course of glomerulonephritis].
Topics: Adolescent; Adult; Azathioprine; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Erythrocyt | 1978 |
Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. II. Influence of medication with prednisone and azathioprine: a histologic and immunohistologic study at the light microscopic and the ultrastructural leve
Topics: Animals; Antibodies; Antigen-Antibody Complex; Antigen-Antibody Reactions; Antigens; Azathioprine; B | 1975 |
Donor-specific IgG antibody and the chronic rejection of human renal allografts.
Topics: Adult; Antibodies, Anti-Idiotypic; Antibody Specificity; Azathioprine; Basement Membrane; Child; Cyc | 1975 |
Factor IX deficiency in the nephrotic syndrome: studies with prothrombin complex concentrate.
Topics: Azathioprine; Coagulants; Factor X; Female; Hemophilia B; Humans; Hypertension; Middle Aged; Nephrot | 1975 |
[Therapy of nephrotic syndrome in childhood].
Topics: Adolescent; Age Factors; Azathioprine; Biopsy; Child; Child, Preschool; Cyclophosphamide; Humans; In | 1976 |
Follow-up of 29 kidney transplant recipients having more than 20 years of functioning allografts.
Topics: Azathioprine; Cyclosporine; Female; Follow-Up Studies; Humans; Kidney Transplantation; Male; Middle | 1992 |
Studies on the antinephritic effects of plant components (6): antinephritic effects and mechanisms of phellodendrine (OB-5) on crescentic-type anti-GBM nephritis in rats (2).
Topics: Animals; Antibodies; Antibodies, Monoclonal; Azathioprine; Basement Membrane; Cholesterol; Creatinin | 1992 |
Prognosis in glomerulonephritis. III. A longitudinal analysis of changes in serum creatinine and proteinuria during the course of disease: effect of immunosuppressive treatment. Report from Copenhagen Study Group of Renal Diseases.
Topics: Azathioprine; Creatinine; Cyclophosphamide; Denmark; Female; Follow-Up Studies; Glomerulonephritis; | 1992 |
The development of proteinuria and focal-segmental glomerulosclerosis in recipients of pediatric donor kidneys.
Topics: Adult; Age Factors; Antilymphocyte Serum; Azathioprine; Child, Preschool; Creatinine; Cyclosporine; | 1991 |
Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anti-Idiotypic; Azathioprine; Basement | 1991 |
The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine.
Topics: Adolescent; Adult; Age Factors; Azathioprine; Child; Child, Preschool; Cyclosporins; Female; Glomeru | 1990 |
Five-year follow-up of graft function and urinary protein excretion in kidney transplant patients immunosuppressed with cyclosporine or azathioprine.
Topics: Azathioprine; Cyclosporins; Follow-Up Studies; Humans; Kidney Transplantation; Proteinuria | 1990 |
Murine chronic graft-versus-host disease as a model of systemic lupus erythematosus: effect of immunosuppressive drugs on disease development.
Topics: Animals; Azathioprine; Cyclophosphamide; Cyclosporins; Deoxyguanosine; Dexamethasone; Disease Models | 1989 |
[Development of hypertension in patients with mesangioproliferative glomerulonephritis].
Topics: Adolescent; Adult; Azathioprine; Bacteriuria; Blood Pressure; Erythrocyte Count; Female; Follow-Up S | 1988 |
Renal survival in membranoproliferative glomerulonephritis (MPGN): role of long-term treatment with non-steroid anti-inflammatory drugs (NSAID).
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chlorambucil; Creati | 1988 |
Safe conversion from cyclosporine.
Topics: Azathioprine; Blood Pressure; Creatinine; Cyclosporins; Graft Rejection; Hemoglobins; Histocompatibi | 1987 |
The glomerular tip lesion: a steroid responsive nephrotic syndrome.
Topics: Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Glomerulonephri | 1987 |
Antinephritic effect of prostaglandin E1 on serum sickness nephritis in rats. (3). Suppression of leukocytes by prostaglandin E1 as a mechanism for preventing immune complex glomerulonephritis.
Topics: Alprostadil; Animals; Antigen-Antibody Complex; Azathioprine; Glomerulonephritis; Leukocyte Count; L | 1986 |
Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Creatinine; Drug Resistance; Female; | 1986 |
Membranoproliferative glomerulonephritis and persistent hypocomplementaemia.
Topics: Adolescent; Adult; Azathioprine; Beta-Globulins; Blood Protein Disorders; Child; Child, Preschool; C | 1970 |
Treatment of lupus nephritis with cyclophosphamide.
Topics: Adolescent; Adult; Age Factors; Azathioprine; Biopsy; Chlorambucil; Cortisone; Cyclophosphamide; Fem | 1970 |
Human renal allografts. Analysis of lesions in long-term survivors.
Topics: Adolescent; Adult; Arteries; Azaserine; Azathioprine; Basement Membrane; Creatine; Cryptococcosis; D | 1971 |
Combined prednisolone, azathioprine, and cyclophosphamide treatment for persistent proliferative glomerulonephritis in adults.
Topics: Adolescent; Adult; Azathioprine; Chlorambucil; Cholesterol; Creatinine; Cyclophosphamide; Female; Gl | 1971 |
[Clinical and morphological studies in nephrotic syndrome. Report on 83 children].
Topics: Azathioprine; Biopsy; Child; Child, Preschool; Cortisone; Cyclophosphamide; Female; Fluorescent Anti | 1972 |
Azathioprine in glomerulonephritis. A long-term study.
Topics: Adolescent; Azathioprine; Basement Membrane; Child; Chronic Disease; Follow-Up Studies; Glomerular F | 1972 |
The effect of azathioprine on lupus glomerulonephritis.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Azathioprine; Biopsy; Blood Proteins; Blood Urea Nitroge | 1972 |
Gamma globulin fragments in urine of kidney transplant patients in relation to rejection crisis.
Topics: Alpha-Globulins; Animals; Antibodies; Antilymphocyte Serum; Azathioprine; Beta-Globulins; Biopsy; Cr | 1970 |
[Successes and failures of immunosuppressive therapy in nephropathies].
Topics: Adult; Anti-Glomerular Basement Membrane Disease; Azathioprine; Chronic Disease; Cortisone; Cyclopho | 1974 |
Immunosuppressive therapy of chronic renal disease.
Topics: Adolescent; Adult; Azathioprine; Child; Chronic Disease; Creatine; Female; gamma-Globulins; Glomerul | 1967 |
Proteinuria and nephrotic syndrome associated with chronic rejection of kidney transplants.
Topics: Azathioprine; Dactinomycin; Glomerulonephritis; Humans; Kidney Transplantation; Nephrotic Syndrome; | 1967 |
Antilymphoid sera in renal allotransplantation.
Topics: Animals; Azathioprine; Creatinine; Dogs; gamma-Globulins; Humans; Immune Sera; Kidney Transplantatio | 1968 |
Immune-complex disease of the kidney associated with chronic hepatitis and cryoglobulinaemia.
Topics: Acute Disease; Adult; Azathioprine; Chronic Disease; Cold Temperature; Cryoglobulins; Diagnosis, Dif | 1969 |
Clinicopathological study of nephrotic syndrome in childhood.
Topics: Adolescent; Age Factors; Azathioprine; Beta-Globulins; Biopsy; Child; Child, Preschool; Cyclophospha | 1970 |
[Penicillamine therapy of chronic liver diseases].
Topics: Azathioprine; Chronic Disease; Drug Hypersensitivity; Female; Glucocorticoids; Hepatitis; Humans; Li | 1974 |
Systemic (allergic?) vasculitis.
Topics: Antigen-Antibody Complex; Azathioprine; Complement System Proteins; Creatinine; Diphenhydramine; Ery | 1974 |
Renal transplants in children.
Topics: 17-Ketosteroids; Adolescent; Adrenocorticotropic Hormone; Azathioprine; Child; Epiphyses, Slipped; F | 1969 |
Lupus nephritis: response to azathioprine.
Topics: Adolescent; Azathioprine; Edema; Female; Glomerular Filtration Rate; Glomerulonephritis; Hematuria; | 1974 |
Successful immunosuppressive treatment of oliguric extracapillary glomerulonephritis.
Topics: Adolescent; Adult; Anuria; Autopsy; Azathioprine; Biopsy; Child; Creatinine; Drug Therapy, Combinati | 1974 |
Renal disease associated with toxic epidermal necrolysis (Lyell's disease).
Topics: Adult; Azathioprine; Biopsy; Blood Urea Nitrogen; Cholesterol; Creatinine; Female; Glomerulonephriti | 1974 |
Experience with penicillamine and azathioprine in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azathioprine; Drug Therapy, Combination; Humans; Penicillamine; Proteinuria | 1974 |
The natural history and treatment of membranous glomerulonephritis.
Topics: Adolescent; Adult; Age Factors; Anticoagulants; Azathioprine; Cyclophosphamide; Female; Follow-Up St | 1973 |
Nucleic acids in the spleen, kidney and liver of the female (NZBxNZW) F1 hybrid mouse.
Topics: Animals; Antibodies, Antinuclear; Autoimmune Diseases; Azathioprine; Chlorpheniramine; Cyclophospham | 1972 |
Schönlein-Henoch nephritis.
Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Biopsy; Child; Child, Preschool; Cyclophosphamide | 1972 |
[Course of nephropathy in systemic lupus erythematosus . Influence of the treatment on clinical symptoms, renal function and histology].
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Antimalarials; Azathioprine; Biopsy; Chlorambucil; | 1972 |
Rapidly progressive glomerulonephritis treated with anticoagulants.
Topics: Adult; Aged; Anticoagulants; Azathioprine; Blood Urea Nitrogen; Creatinine; Dipyridamole; Diuresis; | 1972 |
Progression and remission in the nehprotic syndrome associated with quartan malaria in Uganda.
Topics: Adolescent; Adult; Azathioprine; Biopsy; Blood Protein Electrophoresis; Child; Fluorescent Antibody | 1972 |
Renal transplantation between HL-A identical donor-recipient pairs. Functional and morphological evaluation.
Topics: Adult; Azathioprine; Biopsy; Blood Group Antigens; Blood Urea Nitrogen; Creatinine; Evaluation Studi | 1972 |
Pregnancy in a patient after cadaveric renal transplantation.
Topics: Adult; Agglutinins; Azathioprine; Biopsy; Blood Pressure; Cadaver; Estrogens; Female; Graft Rejectio | 1973 |
A controlled trial of anticoagulants in cadaveric renal transplantation.
Topics: Azathioprine; Blood Coagulation; Cadaver; Creatinine; Drug Evaluation; Fibrin; Graft Rejection; Hemo | 1974 |
Partial lipodystrophy and chronic hypocomplementemic glomerulonephritis.
Topics: Adult; Azathioprine; Cadaver; Complement System Proteins; Creatinine; Dexamethasone; Female; Follow- | 1974 |
[Renal changes following treatment with cytostatic drugs (Trenimon, cyclophosphamide, Imuran). Light and electron microscopic studies on the rat kidney].
Topics: Animals; Azathioprine; Cyclophosphamide; Histocytochemistry; Kidney; Long-Term Care; Male; Microscop | 1972 |
Hepatitis associated antigen (HAA) in urine from serum HAA positive renal transplant recipients.
Topics: Adult; Azathioprine; Creatinine; Female; Glomerular Filtration Rate; Glomerulonephritis; Hepatitis; | 1972 |
[Results of immunosuppressive therapy in chronic nephropathy with special reference to biopsy findings].
Topics: Azathioprine; Biopsy; Chronic Disease; Cyclophosphamide; Glomerulonephritis; Hematuria; Humans; Immu | 1972 |
[Treatment of chronic glomerulopathy].
Topics: Anti-Inflammatory Agents; Azathioprine; Biopsy; Chlorambucil; Chronic Disease; Creatine; Cyclophosph | 1972 |
Treatment of childhood nephrotic syndrome with Imuran.
Topics: Administration, Oral; Azathioprine; Drug Therapy, Combination; Female; Humans; Male; Nephrotic Syndr | 1972 |
Clinicopathological correlations in the nephrotic syndrome due to primary renal disease.
Topics: Acute Disease; Adolescent; Adult; Aged; Autopsy; Azathioprine; Biopsy; Child; Child, Preschool; Chro | 1973 |
Cytostatic treatment of glomerular diseases. I. Effect of azathioprine on serum creatinine and proteinuria. Report from a Copenhagen Study Group of Renal Diseases.
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Child, Preschool; Creatinine; Female; Glo | 1973 |
Cytostatic treatment of glomerular diseases. II. Effect of azathioprine on serum and urine proteins. Report from a Copenhagen Study Group of Renal Diseases.
Topics: Adolescent; Adult; Aged; Albuminuria; Azathioprine; Blood Proteins; Child; Child, Preschool; Female; | 1973 |
Lupus nephritis: clinical course in relation to treatment.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Creatinine; Cyclophosphamide; Female; Follow-Up Studie | 1973 |
Glomerular enlargement in primary renal disease: a quantitative study.
Topics: Adolescent; Adult; Age Factors; Aging; Autopsy; Azathioprine; Biopsy; Child; Child, Preschool; Cyclo | 1974 |
The idiopathic nephrotic syndrome of childhood. A clinical reevaluation of 148 cases.
Topics: Adolescent; Antistreptolysin; Azathioprine; Bacteriuria; Blood Urea Nitrogen; Child; Child, Preschoo | 1974 |
[Treatment of primary proliferative glomerulonephritis by azathioprine].
Topics: Adolescent; Adult; Azathioprine; Female; Fluorescent Antibody Technique; Glomerular Filtration Rate; | 1968 |
Immunosuppressive therapy of proliferative glomerulonephritis in children.
Topics: Adolescent; Autoantibodies; Azathioprine; Child; Complement System Proteins; Creatinine; Female; Flu | 1969 |
Multiple renal abscesses in a patient with rapidly progressive glomerulonephritis while on immunosuppressive treatment.
Topics: Abscess; Adult; Ampicillin; Azathioprine; Creatinine; Escherichia coli; Female; Glomerulonephritis; | 1971 |
Interpretations of transplanted kidney morphology.
Topics: Antibodies, Anti-Idiotypic; Antigen-Antibody Complex; Azathioprine; Basement Membrane; Cell Nucleus; | 1969 |
[Prognosis of the idiopathic nephrotic syndrome in childhood by means of plasma protein clearance].
Topics: Age Factors; Azathioprine; Blood Proteins; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; | 1969 |
[Long term treatment of chronic glomerulonephritis, clinical course and results of renal biopsies].
Topics: Acetates; Adolescent; Adult; Azathioprine; Biopsy; Blood Pressure; Chloroquine; Female; Glomerulonep | 1969 |
Reactivities to horse anti-lymphocyte globulin. II. Serum sickness nephritis with complement alterations in man.
Topics: Antilymphocyte Serum; Azathioprine; Complement System Proteins; Fever; Glomerulonephritis; Hemagglut | 1970 |
[Treatment of glomerulonephritis with metrifudil. Preliminary report].
Topics: Adenosine; Adrenal Cortex Hormones; Azathioprine; Benzyl Compounds; Chronic Disease; Female; Glomeru | 1972 |
Anaphylactoid purpura nephritis: clinicopathological correlations.
Topics: Adolescent; Azathioprine; Biopsy; Child; Child, Preschool; Female; Fibrin; Glomerulonephritis; Human | 1972 |
Experience of immunosuppressive therapy of glomerular disease in adults.
Topics: Adult; Aminohippuric Acids; Azathioprine; Creatinine; Female; Follow-Up Studies; Glomerular Filtrati | 1971 |
Systemic lupus erythematosus with nodular lesions.
Topics: Adult; Azathioprine; Electrophoresis; Humans; Lupus Erythematosus, Systemic; Male; Prednisone; Prote | 1969 |
Selectivity index as a guide to treatment in heavy proteinuria.
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Child; Female; Humans; Immunosuppressive Agents; Kidn | 1969 |
Treatment of lupus nephritis with azathioprine.
Topics: Adolescent; Adult; Autoimmune Diseases; Azathioprine; Female; Humans; Lupus Erythematosus, Systemic; | 1970 |
[Correlations between the histological changes and results of treatment with corticoids and immunosuppressive agents in primary glomerulonephritis].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Azathioprine; Chlorambucil; Glomerulonephritis; Humans; | 1970 |
Monoclonal gammopathy, glomerulonephritis and the nephrotic syndrome.
Topics: Azathioprine; Biopsy; Blood Proteins; Cholesterol; Creatinine; Glomerulonephritis; Humans; Immunoele | 1970 |
Deterioration of renal function after discontinuation of long-term prednisone-azathioprine therapy in primary renal disease.
Topics: Adult; Azathioprine; Drug Tolerance; Female; Glomerulonephritis; Humans; Kidney; Kidney Diseases; Ki | 1970 |
Management of the nephrotic syndrome in children.
Topics: Azathioprine; Child; Child, Preschool; Cyclophosphamide; Diuretics; Edema; Female; Humans; Infant; M | 1970 |
[Treatment of kidney glomerular diseases with cytostatics].
Topics: Azathioprine; Creatinine; Glomerulonephritis; Humans; Nephrotic Syndrome; Proteinuria | 1970 |
[Treatment of chronic glomerulonephritis with imuran].
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Blood Sedimentation; Child; Chronic Disease; Colic; D | 1970 |
[Familial nephrotic syndrome].
Topics: Acute Kidney Injury; Adolescent; Adrenal Cortex Hormones; Age Factors; Azathioprine; Biopsy; Child; | 1970 |
[The long-term therapy of glomerulonephritis without renal insufficiency].
Topics: Azathioprine; Chronic Disease; Cortisone; Diet Therapy; Ethacrynic Acid; Furosemide; Glomerulonephri | 1968 |
Malaria prophylaxis and immunosuppressant therapy in management of nephrotic syndrome associated with quartan malaria.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Female; Glomerulonephritis; Humans; Kidney Glomer | 1968 |
Persistent proteinuria.
Topics: Adolescent; Adult; Azathioprine; Female; Humans; Male; Nephrotic Syndrome; Proteinuria | 1968 |
[Therapeutic possibilities in chronic glomerulonephritis].
Topics: Adolescent; Adult; Azathioprine; Chlorambucil; Chronic Disease; Glomerulonephritis; Humans; Immunosu | 1969 |
Azathioprine for the nephrotic syndrome.
Topics: Adolescent; Adult; Azathioprine; Humans; Middle Aged; Nephrotic Syndrome; Proteinuria | 1969 |
Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Biopsy; Child; Child, Preschool; Cyc | 1966 |
[Apropos of differential diagnosis of pulmonary hemosiderosis].
Topics: Adult; Anemia, Hypochromic; Anti-Glomerular Basement Membrane Disease; Azathioprine; Diagnosis, Diff | 1966 |